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Abstract: A human monoclonal heterosubtypic antibody, MAb 3.1, with its heavy chain encoded by
VH3-30, was isolated using phage display with immobilized hemagglutinin (HA) from influenza virus
A/Japan/305/1957(H2N2) as the target. Antibody 3.1 potently neutralizes influenza viruses from the
H1a clade (i.e., H1, H2, H5, H6) but has little neutralizing activity against the H1b clade. Its crystal
structure in complex with HA from a pandemic H1N1 influenza virus, A/South Carolina/1/1918(H1N1),
revealed that like other heterosubtypic anti-influenza virus antibodies, MAb 3.1 contacts a hydrophobic
groove in the HA stem, primarily us- ing its heavy chain. However, in contrast to the closely related
monoclonal antibody (Mab) FI6 that relies heavily on HCDR3 for binding, MAb 3.1 utilizes residues
from HCDR1, HCDR3, and framework region 3 (FR3). Interestingly, HCDR1 of MAb 3.1 adopts an
alpha-helical conformation and engages in hydrophobic interactions with the HA very similar to those
of the de novo in silico-designed and affinity-matured synthetic protein HB36.3. These findings improve
our understanding of the molecular requirements for binding to the conserved epitope in the stem of
the HA protein and, therefore, aid the development of more universal influenza vaccines targeting these
epitopes. IMPORTANCE Influenza viruses rapidly evade preexisting immunity by constantly alter-
ing the immunodominant neutralizing antibody epitopes (antigenic drift) or by acquiring new envelope
serotypes (antigenic shift). As a consequence, the majority of antibodies elicited by immunization or
infection protect only against the immunizing or closely related strains. Here, we describe a novel mon-
oclonal antibody that recognizes the conserved heterosubtypic epitope in the stem of influenza A virus
hemagglutinin. This antibody, referred to as MAb 3.1, recognizes its epitope in a manner that resembles
recognition of a similar epitope by the de novo in silico-designed and affinity-matured synthetic protein
HB36.3. Thus, besides providing novel insights into the molecular interactions between heterosubtypic
antibodies and influenza virus hemagglutinin, MAb 3.1 demonstrates that de novo in silico-designed and
affinity-matured synthetic proteins can foretell naturally selected antibody binding. This knowledge will
aid development of a pan-influenza virus vaccine.
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Abstract	  	  21	  
A	  human	  monoclonal	  heterosubtypic	  antibody,	  mAb	  3.1,	  with	   its	  heavy	  chain	  encoded	  22	  
by	   VH3-­‐30,	   was	   isolated	   using	   phage	   display	   with	   immobilized	   hemagglutinin	   from	  23	  
A/Japan/305/1957(H2N2)	   as	   the	   target.	   Antibody	   3.1	   potently	   neutralizes	   influenza	  24	  
viruses	  from	  the	  H1a	  clade	  (i.e.	  H1,	  H2,	  H5,	  H6),	  but	  has	  little	  neutralizing	  activity	  against	  25	  
the	  H1b	  clade.	  Its	  crystal	  structure	  in	  complex	  with	  HA	  from	  a	  pandemic	  H1N1	  influenza	  26	  
virus	   A/South	   Carolina/1/18(H1N1)	   revealed	   that,	   like	   other	   heterosubtypic	   anti-­‐27	  
influenza	  antibodies,	  mAb3.1	  contacts	  a	  hydrophobic	  groove	   in	  the	  HA	  stem,	  primarily	  28	  
using	   its	   heavy	   chain.	   However,	   in	   contrast	   to	   the	   closely	   related	  mAb	   FI6	   that	   relies	  29	  
heavily	  on	  HCDR3	  for	  binding,	  mAb	  3.1	  utilizes	   residues	   from	  HCDR1,	  HCDR3	  and	  FR3.	  30	  
Interestingly,	  HCDR1	  of	  mAb	  3.1	  adopts	  anα-­‐helical	  conformation	  and	  engages	  in	  very	  31	  
similar	   hydrophobic	   interactions	   with	   the	   HA	   as	   the	   de	   novo	   in	   silico	   designed	   and	  32	  
affinity	  matured	  synthetic	  protein	  HB36.3.	  These	   findings	   improved	  our	  understanding	  33	  
of	  the	  molecular	  requirements	  for	  binding	  to	  the	  conserved	  epitope	  in	  the	  stem	  of	  the	  34	  
HA	   protein	   and,	   therefore,	   aid	   the	   development	   of	  more	   universal	   influenza	   vaccines	  35	  
targeting	  these	  epitopes.	  	  36	  
Importance	  37	  
Influenza	   viruses	   rapidly	   evade	   pre-­‐existing	   immunity	   by	   constantly	   altering	   the	  38	  
immunodominant	  neutralizing	  antibody	  epitopes	   (antigenic	  drift),	   or	  by	  acquiring	  new	  39	  
envelope	   serotypes	   (antigenic	   shift).	   As	   a	   consequence,	   the	   majority	   of	   antibodies	  40	  
elicited	   by	   immunization	   or	   infection	   only	   protect	   against	   the	   immunizing	   or	   closely	  41	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related	   strains.	   Here,	   we	   describe	   a	   novel	   monoclonal	   antibody	   recognizing	   the	  42	  
conserved	  heterosubtypic	  epitope	   in	   the	  stem	  of	   influenza	  A	  virus	  hemagglutinin.	  This	  43	  
antibody,	   referred	   to	   as	  mAb	   3.1,	   recognizes	   its	   epitope	   in	   a	  manner	   that	   resembles	  44	  
recognition	  of	  a	  similar	  epitope	  by	   the	  de	  novo	   in	  silico	  designed	  and	  affinity	  matured	  45	  
synthetic	   protein	   HB36.3.	   Thus,	   besides	   providing	   novel	   insights	   into	   the	   molecular	  46	  
interactions	  between	  heterosubtypic	  antibodies	  and	  influenza	  virus	  hemagglutinin,	  mAb	  47	  
3.1	  demonstrates	  that	  de	  novo	  in	  silico	  designed	  and	  affinity	  matured	  synthetic	  proteins	  48	  
can	  foretell	  naturally	  selected	  antibody	  binding.	  This	  knowledge	  will	  aid	  development	  of	  49	  
a	  pan-­‐influenza	  vaccine.	  50	  
Introduction	  	  51	  
Hemagglutinin	  (HA),	  the	  surface	  protein	  responsible	  for	  receptor	  attachment	  and	  entry	  52	  
of	  influenza	  A	  viruses,	  has	  currently	  been	  classified	  into	  18	  distinct	  subtypes	  (H1-­‐H18)	  53	  
that	  can	  be	  combined	  into	  two	  separate	  phylogenetic	  groups	  (1,	  2).	  HA	  is	  initially	  54	  
synthesized	  as	  an	  inactive	  form	  (HA0)	  that	  is	  processed	  to	  its	  fusion-­‐active	  form	  by	  55	  
cleavage	  into	  covalently	  linked	  HA1	  and	  HA2	  subunits.	  These	  assemble	  as	  trimers	  of	  56	  
heterodimers	  consisting	  of	  an	  apical	  globular	  head	  from	  the	  HA1	  subunit	  that	  is	  57	  
responsible	  for	  mediated	  receptor	  binding,	  and	  a	  stem	  region	  containing	  the	  fusion	  58	  
machinery,	  which	  is	  constructed	  by	  HA2	  and	  the	  N	  and	  C-­‐termini	  of	  HA1.	  Antibodies	  59	  
elicited	  during	  infection	  and	  immunization	  bind	  to	  highly	  antigenic	  sites	  surrounding	  the	  60	  
receptor	  binding	  site	  on	  HA1,	  and	  typically	  interfere	  with	  receptor	  binding	  (3-­‐6).	  As	  61	  
these	  antigenic	  sites	  are	  also	  subject	  to	  the	  highest	  antigenic	  variation,	  most	  antibodies	  62	  
4	  
	  
binding	  influenza	  HA	  are	  highly	  strain-­‐specific,	  and	  only	  recognize	  the	  eliciting	  or	  closely	  63	  
related	  virus	  strains.	  However,	  antibodies	  to	  the	  receptor	  binding	  site	  have	  recently	  64	  
been	  discovered	  that	  have	  greater	  breadth	  (7-­‐14).	  65	  
Currently,	   only	   influenza	   viruses	   of	   the	   H1	   and	   H3	   subtypes	   circulate	   in	   the	   human	  66	  
population.	  Nevertheless,	   zoonotic	   infections	  with	  avian	  or	   swine	  viruses	  are	   reported	  67	  
on	  a	  regular	  basis,	  indicating	  that,	  to	  some	  degree,	  the	  species	  barrier	  is	  permeable	  for	  68	  
at	   least	   some	   other	   subtypes	   of	   influenza	   viruses	   (15-­‐18).	   Although	   most	   of	   these	  69	  
zoonotic	  infections	  are	  relatively	  benign,	  transmission	  of	  avian	  influenza	  A	  viruses	  of	  the	  70	  
H5N1	  or	  the	  H7N9	  subtypes	  appears	  to	  be	  lethal	  for	  30	  to	  60%	  of	  all	  infected	  individuals	  71	  
who	  are	  diagnosed.	  For	  H7N9	  viruses,	  some	  limited	  human-­‐to-­‐human	  transmission	  has	  72	  
been	  documented	   (19)	  but	   the	  viral	  HA	  has	  not	  yet	  evolved	   to	  efficiently	  bind	  human	  73	  
receptors	  (20).	  As	  the	  usefulness	  of	  currently	  available	  drugs	  is	  rapidly	  decreasing,	  there	  74	  
is	  a	  need	   for	  new	  treatment	  options.	  Moreover,	  development	  of	  a	  pan-­‐influenza	  virus	  75	  
vaccine	   that	  made	   annual	   reformulation	   and	   application	   of	   the	   vaccine	   obsolete,	   and	  76	  
also	  protected	  against	  novel	  emerging	  influenza	  viruses,	  would	  be	  highly	  desirable.	  The	  77	  
discovery	   of	   heterosubtypic	   antibodies,	   i.e.	   antibodies	   that	   recognize	   more	   than	   one	  78	  
subtype	   of	   influenza	   A	   virus,	   indicates	   that	   there	   are	   highly	   conserved	   neutralizing	  79	  
antibody	  epitopes	  on	  HA	  that	  could	  be	  exploited	  for	  the	  development	  of	  a	  pan-­‐influenza	  80	  
virus	  vaccine.	  	  81	  
The	   first	   heterosubtypic	   monoclonal	   antibody	   (hmAb)	   isolated,	   C179,	   was	   elicited	   by	  82	  
hyperimmunization	  of	  mice	  with	  an	  H2N2-­‐expressing	  human	  virus	  around	  20	  years	  ago	  83	  
(21,	   22).	   Recently,	   several	   human	   heterosubtypic	   antibodies	   have	   been	   isolated	   and	  84	  
5	  
	  
their	  epitopes	  characterized	   (7,	  23-­‐32).	  With	   the	  exception	  of	   the	  exclusively	  group	  2-­‐85	  
specific	   heterosubtypic	   antibodies	   CR8020	   and	   CR8043	   (27,	   28)	   that	   bind	   to	   a	   more	  86	  
membrane-­‐proximal	   epitope,	   all	   other	   heterosubtypic	   antibodies	   recognize	  87	  
approximately	   the	   same	   epitope	   on	   the	   stem	   of	   influenza	   A	   HA.	   This	   epitope,	   which	  88	  
corresponds	  to	  a	  hydrophobic	  groove	  framed	  by	  residues	  18-­‐52	  and	  290-­‐330	  of	  HA1	  in	  89	  
combination	   with	   1-­‐21	   and	   38-­‐60	   of	   HA2,	   is	   very	   conserved	   amongst	   all	   subtypes	   of	  90	  
influenza	  A	  and,	  to	  some	  extent	  also,	  with	  influenza	  B	  viruses	  (25).	  	  91	  
Several	  antibodies	  binding	  to	  this	  epitope	  are	  encoded	  by	  VH1-­‐69	  (F10,	  CR6261,	  CR9114,	  92	  
3C4)	   or	   VH3-­‐30	   (FI6,	   1C4)	   germline	   genes	   and	   preferentially	   bind	   HA	   subtypes	   of	  93	  
phylogenetic	   group	   1	   (H1,	   H2,	   H5,	   H6,	   H8,	   H9,	   H11,	   H12,	   H13,	   H16).	   Only	   a	   few	  94	  
monoclonal	   heterosubtypic	   antibodies	   capable	   of	   neutralizing	   viruses	   from	   both	  95	  
phylogenetic	   groups	   have	   been	   described	   (23,	   25,	   29).	   To	   date,	   only	   six	   human	  96	  
heterosubtypic	  antibodies	  to	  this	  epitope	  have	  been	  described	  (PN-­‐SIA49,	  1E1,	  1F2,	  1F4,	  97	  
1G1,	  3E1)	  that	  are	  not	  encoded	  by	  the	  VH1-­‐69	  or	  VH3-­‐30	  germline	  genes;	  24,	  29).	  Five	  of	  98	  
these	  antibodies	  use	  VH3-­‐23	  and	  the	  other	  the	  VH4-­‐4	  heavy	  chain	  germline	  gene	  (24,	  29).	  99	  
These	   antibodies	   are	   either	   specific	   for	   phylogenetic	   group	   1	   (24),	   or	   can	   neutralize	  100	  
viruses	  from	  both	  phylogenetic	  groups	  (29).	  101	  
VH1-­‐69-­‐encoded	   heterosubtypic	   antibodies	   primarily	   use	   their	   heavy	   chain	   to	   contact	  102	  
the	   HA	   protein.	   Although	   VH1-­‐69	   antibodies	   devoid	   of	   somatic	   hypermutation	   do	   not	  103	  
recognize	  soluble	  HA,	  they	  can	  trigger	  B	  cell	  receptor	  signaling	  when	  engaged	  by	  HA	  as	  104	  
an	  IgM	  molecule	  on	  the	  surface	  of	  B	  cells	  (33).	  From	  the	  available	  crystal	  structures,	   it	  105	  
can	  be	  deduced	  that	  positions	  49,	  111	  and	  21	  in	  HA2,	  as	  well	  as	  the	  presence	  or	  absence	  106	  
6	  
	  
of	   a	   glycan	   at	   position	   38	  of	  HA1,	   account	   for	   the	  main	   differences	   between	   the	   two	  107	  
phylogenetic	   groups	   (23,	   25,	   26,	   31).	   Antibodies	   capable	   of	   overcoming	   these	  108	  
differences	   use	   the	   diversity	   of	   their	   complementarity-­‐determining	   regions	   (CDR)	   to	  109	  
accommodate	   such	   differences	   (23,	   25).	   The	   VH3-­‐30-­‐encoded	   FI6,	   for	   instance,	   is	  110	  
characterized	   by	   a	   long	   HCDR3	   loop	   (22	   aa)	   that	   provides	   the	   hydrophobic	   residues	  111	  
(mainly	   aromatics)	   that	   seem	   to	   be	   required	   for	   crucial	   interactions	   with	   the	  112	  
hydrophobic	   groove	   in	   the	   HA	   stem	   (i.e.	   Leu100a,	   Tyr100c,	   Phe100d,	   Trp100f).	   In	  113	  
contrast,	   murine	   mAb	   C179,	   and	   all	   VH1-­‐69-­‐encoded	   antibodies	   including	   CR9114	  114	  
described	  to	  date,	  contact	  this	  groove	  using	  hydrophobic	  residues	  from	  all	  of	  the	  HCDRs	  115	  
of	  their	  heavy	  chain	  (25,	  26).	  Additional	  contacts	  can	  assist	  the	  interaction	  of	  the	  heavy	  116	  
chain	  with	  the	  hydrophobic	  groove	  and	  can	  either	   include	  residues	  of	  LCDR1	  (Phe27D,	  117	  
Asn28,	  Tyr29;	  FI6),	  or	  HFR3	  (Asp72,	  Ile	  or	  Asp73,	  Phe74;	  CR6261	  and	  CR9114).	  118	  
Materials	  and	  Methods	  119	  
Viruses	  120	  
Influenza	  viruses	  were	  propagated	  at	  a	  multiplicity	  of	  infection	  (MOI)	  of	  0.001	  on	  MDCK	  121	  
and	  harvested	  36	  to	  76	  hours	  after	  infection.	  Alternatively,	  embryonated	  hen	  eggs	  (10-­‐122	  
11	  days	  after	  gestation)	  were	   inoculated	  with	  titrated	  amounts	  of	  virus	  and	   incubated	  123	  
for	  48h	  at	  37°C	  before	  the	  allantoic	  liquid	  was	  harvested.	  Virus-­‐containing	  supernatant	  124	  
or	  allantoic	  liquid	  was	  stored	  in	  aliquots	  at	  -­‐70°C.	  	  125	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Reassortant	  viruses	  126	  
If	   not	   available,	   HA	   genes	   of	   interest	   were	   amplified	   and	   cloned	   into	   pHW2000	   as	  127	  
described	   by	   Hoffman	   et	   al.	   (34).	   Point	   mutations	   were	   introduced	   using	   the	  128	  
QuikChange	   II	   mutagenesis	   kit	   (Agilent)	   according	   to	   the	  manufacturer’s	   instructions.	  129	  
For	   the	   generation	   of	   reassortant	   viruses,	   a	   pHW2000-­‐derived	   plasmid	   containing	  130	  
segment	  4	  was	  mixed	  with	  plasmids	  containing	  the	  remaining	  7	  genome	  segments	  from	  131	  
A/Puerto	  Rico/8/1934(H1N1),	  and	  transfected	  into	  a	  mixture	  of	  293T	  and	  MDCK	  cell	  as	  132	  
described	  by	   (35).	  Three	  days	  after	   transfection,	  presence	  of	  virus	  was	  determined	  by	  133	  
hemagglutination	  and	  clarified	  supernatant	  was	  used	  to	  infect	  107	  MDCK	  cells	  in	  a	  T150	  134	  
flask.	  Three	  days	  later,	  P1	  supernatant	  was	  harvested	  and	  frozen	  in	  aliquots	  at	  -­‐70°C.	  	  135	  
Library	  construction	  and	  phage	  display	  selection	  of	  cross-­‐reactive	  Fab	  clones	  136	  
The	  antibody	  phage	  display	  library	  was	  prepared	  according	  to	  Barbas	  et	  al.	  (36).	  In	  brief,	  137	  
donor	   13	   (RI-­‐13),	   a	   healthy	   Caucasian	   male	   of	   32	   years	   displaying	   low	   to	   average	  138	  
heterosubtypic	  antibody	  titers	   in	  ELISA	  and	   in	  vitro	  neutralization	  assays,	  was	  selected	  139	  
for	  this	  study.	  According	  to	  the	  questionnaire	  filled	  at	  the	  time	  of	  the	  blood	  draw,	  donor	  140	  
13	   had	   been	   vaccinated	   6	   times	   against	   seasonal	   influenza,	   had	   not	   knowingly	   been	  141	  
exposed	   to	   avian	   influenza	   A	   viruses,	   and	   did	   not	   experience	   an	   influenza	   episode	   or	  142	  
vaccination	  during	  the	  3	  months	  prior	  to	  the	  blood	  donation	  (April	  4th	  2008).	  Peripheral	  143	  
blood	  mononuclear	  cells	   (PBMC)	  were	   isolated	  by	  Ficoll	  density-­‐cushion	  centrifugation	  144	  
on	   the	   day	   of	   the	   draft,	   and	   cells	  were	   cryopreserved	   in	   aliquots	   of	   2x107	   PBMCs	   for	  145	  
later	  use.	  	  146	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At	  the	  day	  of	  the	  library	  preparation,	  ~1.6x106	  mature	  B	  cells	  were	  isolated	  from	  thawed	  147	  
PBMCs	   using	   anti	   CD22-­‐coated	   MACS	   beads	   (Milteny	   Biotech)	   according	   to	   the	  148	  
manufacturer’s	   instructions.	  Total	  RNA	  was	   isolated	  from	  B	  cells	  using	  RNeasy	  Mini	  Kit	  149	  
columns	   (Qiagen)	   and	  was	   reverse	   transcribed	   into	   cDNA	   using	   Superscript	   II	   reverse	  150	  
transcriptase	   from	   Invitrogen	   and	   oligo	   dT	   primers	   (Promega)	   according	   to	   the	  151	  
manufacturer’s	   recommendations.	   Immunoglobulin	   variable	   regions	   were	   PCR	  152	  
amplified,	   and	   assembled	   into	   Fab	   fragments	   in	   three	   subsequent	   PC	   reactions	  153	  
according	   to	   (36).	   Ligation	   of	   the	   assembled	   Fab	   fragments	   into	   the	   pComb3X	   phage	  154	  
display	  vector	  yielded	  1.5x109	  plasmid	  clones	   that	  gave	   rise	   to	  more	   than	  1013	  plaque	  155	  
forming	  units	  after	  super-­‐infection	  with	  a	  helper	  phage.	  	  156	  
For	   the	   panning,	   biotinylated	   and	   trypsin-­‐cleaved	   hemagglutinin	   from	  157	  
A/Japan/1957(H2N2)	   was	   immobilized	   on	   streptavidin	   coated	   magnetic	   beads	  158	  
(Promega).	   Approximately	   2.5x1012	   of	   phages	   were	   combined	   with	   15µg	   of	   HA	  159	  
immobilized	  on	  300µl	  magnetic	  beads	   (final	  concentration	  of	   immobilized	  HA	  was	  100	  160	  
nM)	  for	  the	  first	  round	  of	  selection.	  A	  total	  of	  four	  panning	  rounds	  were	  conducted	  with	  161	  
increasing	  stringency	  by	  using	  less	  protein-­‐coated	  beads	  (2µg	  of	  HA	  immobilized	  on	  50µl	  162	  
magnetic	  beads)	  and	  increasing	  the	  number	  of	  washes	  (1st	  round:	  2x	  TBST;	  2nd	  round:	  163	  
4x	  TBST,	  1xTBS;	  3rd	  round:	  6x	  TBST,	  1xTBS;	  4th	  round:	  8xTBST,	  1xTBS;	  TBST	  corresponds	  164	  
to	  TBS	  supplemented	  with	  0.05%	  Tween	  20).	  Phage	  clones	  obtained	  after	   the	  3rd	  and	  165	  
4th	  rounds	  were	  screened	  for	  binding	  to	  various	  HAs	  in	  ELISA,	  and	  positive	  clones	  were	  166	  
sequenced.	  One	  clone,	  referred	  to	  as	  mAb	  3.1,	  was	  chosen	  for	  further	  analysis	  based	  on	  167	  
its	  sequence	  and	  binding	  properties.	  	  168	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Expression	  and	  purification	  of	  recombinant	  HAs	  169	  
Recombinant	  HA,	   stabilized	   by	   a	  His-­‐tagged	   trimerization	   domain,	  was	   expressed	   into	  170	  
the	   supernatant	   of	   baculovirus-­‐infected	   SF9	   insect	   cells	   as	   previously	   described	   (37).	  171	  
After	  4	  days,	   supernatant	  was	  harvested	  and	  soluble	  protein	  purified	  by	  metal	  affinity	  172	  
chromatography	   (Ni-­‐NTA	   columns,	   GE	   Healthcare).	   Purified	   HA	   was	   proteolytically	  173	  
processed	   into	   its	   HA1	   and	   HA2	   subunits	   using	   10U	   of	   TPCK-­‐treated	   trypsin	   (bovine	  174	  
pancrease,	  Sigma	  Aldrich)	  per	  1	  μg	  of	  HA	  for	  1h	  at	  RT.	  Following	  digestion,	  trypsin	  was	  175	  
removed	  by	  size	  exclusion	  chromatography	  using	  a	  200ml	  Superdex®	  S200	  gel	  filtration	  176	  
column	  (GE	  Healthcare).	  For	  further	  experiments,	  only	  the	  fraction	  corresponding	  to	  the	  177	  
HA	  trimer	  was	  used.	  178	  
Expression	  and	  purification	  of	  recombinant	  Fab	  or	  IgG1	  molecules	  179	  
For	  purification	  of	  Fab	  3.1,	  the	  protocol	  by	  Barbas	  et	  al.	  was	  followed	  (36).	  Briefly,	  the	  180	  
phagemid	   containing	   the	   3.1	   sequences	   was	   transformed	   into	   chemically	   competent	  181	  
TOP	   10	   E.	   coli	   cells	   (Invitrogen).	   A	   single	   colony	   from	   the	   transformation	   plate	   was	  182	  
inoculated	   into	   LB	   supplemented	   with	   carbenicilin	   (50	   μg/ml),	   and	   grown	   under	  183	  
agitation	   (200	   rpm)	   at	   37⁰C	   over	   night.	   This	   pre-­‐culture	  was	   then	   diluted	   1:100	   in	   SB	  184	  
supplemented	  with	   carbenicilin	   (50	   μg/ml)	   and	   20	  mM	  MgCl2,	   and	  was	   grown	   under	  185	  
agitation	  (250	  rpm)	  at	  37⁰C	  for	  24h.	  Bacterial	  cells	  were	  harvested	  by	  centrifugation	  and	  186	  
disrupted	  using	  a	  sonicator	  (Branson	  Sonifier	  250).	  Lysate	  was	  cleared	  by	  centrifugation	  187	  
(>13500rpm	  for	  60min)	  and	  filtration	  at	  0.2	  µm,	  and	  Fab	  fragments	   isolated	  by	  affinity	  188	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chromatography	  using	  protein	  G	  slurry	  (GE	  healthcare).	  Bound	  Fab	  was	  eluted	  from	  the	  189	  
column	  using	  0.1	  M	  glycine	  pH	  3,	  and	  stored	  in	  PBS	  at	  4°C	  after	  buffer	  exchange.	  190	  
For	   expression	   of	   soluble	   IgG	   3.1,	   FI6	   and	   the	   FI6-­‐3.1	   hybrid,	   the	   variable	   regions	   of	  191	  
heavy	   and	   light	   chains	   were	   cloned	   into	   the	   corresponding	   pIg-­‐Abvec	   plasmids	   (38).	  192	  
Proteins	  were	  expressed	  by	  transient	  transfection	  of	  293T	  cells	  (30	  μg	  of	  each	  plasmid	  193	  
combined	  with	  120	  µg	  PEI	  per	  1	  T150	  flask).	  The	  cell	  supernatant	  was	  harvested,	  spun	  194	  
down	   at	   3000	   rpm	   5	   min	   and	   then	   at	   8000	   rpm	   10	   min,	   filtered	   at	   0.2	   µM,	   and	  195	  
recombinant	   IgG1	   was	   purified	   by	   affinity	   chromatography	   using	   protein	   G	   columns.	  196	  
Eluted	  IgG1	  was	  re-­‐buffered	  into	  PBS	  and	  stored	  at	  4°C.	  197	  
ELISA	  198	  
Binding	  of	  IgG	  3.1,	  FI6	  and	  FI6-­‐3.1	  to	  recombinant	  HA	  proteins	  (non-­‐trypsin	  cleaved	  H1	  199	  
from	   A/Puerto	   Rico/8/34(H1N1)	   and	   H7	   from	   A/FPV/Bratislava/79(H7N7),	   trypsin-­‐200	  
cleaved	   and	   non-­‐digested	   H3	   from	   A/Moscow/10/99(H3N2),	   and	   trypsin-­‐cleaved	   H12	  201	  
from	  A/Duck/Alberta/60/76(H12N5))	  was	  detected	  by	  ELISA.	  To	  this	  end,	  half-­‐area,	  high	  202	  
binding	  capacity	  plates	  (Costar)	  were	  coated	  with	  25	  μl/well	  of	  2	  μg/ml	  HA	  in	  PBS	  at	  4	  ⁰C	  203	  
over	  night.	  Plates	  were	  then	  blocked	  with	  2%	  milk	  in	  PBS.	  IgG	  were	  titrated	  in	  0.2%	  milk	  204	  
PBS,	  transferred	  to	  the	  blocked	  ELISA	  plates,	  and	  allowed	  to	  bind	  for	  1	  h.	  After	  washing	  205	  
with	   TBST	   (0.1%	   Tween),	   bound	   Ig	  was	   detected	   using	   a	   goat	   anti-­‐human	   kappa-­‐HRP	  206	  
secondary	  antibody	   (Southern	  Biotech)	  and	  developed	  using	  TMB	  as	  a	   substrate.	  As	  a	  207	  
negative	   control,	   HIV	   gp120-­‐specific	   and	   293T-­‐cell	   expressed	   mAb	   b12	   antibody	   was	  208	  
used.	  	  209	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Neutralization	  of	  Influenza	  A	  viruses	  210	  
Titrated	  amounts	  of	   IgG	  3.1,	  or	   IgG1-­‐b12	  as	  negative	   control,	  were	  mixed	   in	   triplicate	  211	  
with	  a	  fixed	  amount	  of	  Influenza	  A	  virus	  corresponding	  to	  MOI	  2-­‐3	  (~	  105	  pfu)	  in	  DMEM	  212	  
medium	   supplemented	  with	   0.2%	  BSA,	   20	  mM	  HEPES,	   50U/ml	   penicillin	   and	   50µg/ml	  213	  
streptomycin	   (DMEM/BSA).	   After	   incubation	   at	   37⁰C/5%CO2	   for	   2h,	   the	   mAb-­‐virus	  214	  
mixture	  was	  transferred	  to	  PBS-­‐washed,	  sub-­‐confluent	  MDCK	  cells	  seeded	  into	  96-­‐well	  215	  
tissue	   culture	   plates	   the	   day	   before	   (1	   to	   2x104	   cells/	   well,	   TPP),	   and	   incubated	   at	  216	  
37⁰C/5%	  CO2	  for	  1h	  to	  allow	  infection.	  Residual	  virus	  and	  antibody	  was	  aspirated,	  cells	  217	  
washed	  with	  PBS,	  and	  DMEM/BSA	  was	  added.	  Following	  incubation	  at	  37°C/5%	  CO2	  for	  218	  
4.5	  to	  7h	  (depending	  on	  the	  growth	  kinetics	  of	   the	  virus	   isolate),	  cells	  were	  fixed	  with	  219	  
methanol,	   washed	   and	   stained	   with	   a	   3µg/ml	   FITC-­‐labeled	   antibody	   to	   influenza	   NP	  220	  
(ATCC	   HB-­‐65™)	   in	   PBS	   containing	   1%	   BSA	   at	   4°C	   overnight.	   After	   washing,	   the	   FITC-­‐221	  
labeled	  antibody,	  cells	  were	  stained	  with	  DAPI	  to	  control	  for	  cell	  density	  or	  cell	  loss.	  The	  222	  
corresponding	   fluorescence	  was	   then	  measured	   in	  each	  well	  at	  16	   (FITC)	  and	  9	   (DAPI)	  223	  
distinct	   locations	   in	   a	   Perkin	   Elmer	   plate	   reader.	   For	   each	   well,	   the	   average	   for	   all	  224	  
individual	   fluorescence	  measuring	  points	  was	  calculated	  and	  used	   for	   further	  analysis.	  225	  
EC50	  values	  were	  determined	  in	  Prism	  5	  (GraphPad	  Software)	  using	  iterative	  computing	  226	  
of	  the	  best	  fitting	  Hill	  equation.	  227	  
Infectivity	  reduction	  assay	  228	  
40µl	  of	  DMEM/BSA	  containing	  60µg/ml	  of	  the	  antibody	  of	  interest	  were	  mixed	  with	  80µl	  229	  
of	  untitrated	  virus	  supernatant	  and	  incubated	  for	  90min	  at	  37°C/CO2.	  As	  a	  control,	  the	  230	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same	  amount	  of	  virus	  was	  mock	  incubated	  with	  DMEM/BSA	  without	  antibody.	  Following	  231	  
incubation	  for	  90min	  at	  37°/5%CO2,	  non-­‐neutralized	  infectivity	  was	  determined	  by	  serial	  232	  
diluting	  the	  virus/antibody	  mixture	  1	  in	  2,	  and	  infection	  of	  2-­‐4x104	  MDCK	  cells	  with	  this	  233	  
dilution	  series.	   Infection	  was	  allowed	  to	  proceed	  5-­‐6	  hours	  before	  cells	  were	  fixed	  and	  234	  
stained	  with	  a	  FITC-­‐labeled	  antibody	  to	  NP,	  as	  described	  above.	  235	  
Structural	  homology	  search	  236	  
To	   identify	   the	   closest	   structural	   homologs	   of	   mAb	   3.1,	   the	   coordinates	   for	   the	   3.1	  237	  
antibody	  heavy	  and	   light	  chain	  were	  extracted	   from	  the	  structure	  of	   the	  complex	  and	  238	  
submitted	   to	   the	   PDBe	   (http://www.ebi.ac.uk/msd-­‐srv/ssm/ssmstart.html)	   or	   DALI	  239	  
(http://ekhidna.biocenter.helsinki.fi/dali_server/)	  structural	  homology	  search	  engines	  as	  240	  
a	  pdb	  file.	  	  241	  
KD	  Determination	  242	  
KD	   values	   were	   determined	   by	   bio-­‐layer	   interferometry	   (BLI)	   using	   an	   Octet	   Red	  243	  
instrument	   (ForteBio,	   Inc.)	   as	   described	   in	   (10).	   Biotinylated	  HAs	  were	   used	   for	   these	  244	  
measurements.	  HAs	  at	  ~10-­‐50	  µg/mL	  in	  1X	  kinetics	  buffer	  (1X	  PBS,	  pH	  7.4,	  0.01%	  BSA,	  245	  
and	  0.002%	  Tween	  20)	  were	  loaded	  onto	  streptavidin-­‐coated	  biosensors	  and	  incubated	  246	  
with	  varying	  concentrations	  of	  mAb3.1	  Fab.	  If	  no	  initial	  binding	  was	  observed	  using	  the	  247	  
above	  conditions,	  mAb3.1	  concentrations	  up	  to	  1µM	  were	  used	  to	  detect	  whether	  any	  248	  
changes	   could	   be	   observed	   in	   the	   binding	   curves.	   For	   determination	   of	   the	   binding	  249	  
kinetics	  of	  mAb	  3.1,	  a	  CM5	  Biacore	  chip	  was	  covalently	  coated	  with	  goat	  anti-­‐human	  Fc	  250	  
(Bethyl	  Laboratories,	  A80-­‐104	  A)	  at	  0.1	  mg/ml	  to	  a	  final	  density	  of	  1342	  response	  units	  251	  
13	  
	  
(RU),	  before	  purified	  mAb	  3.1	  at	  0.01	  mg/ml	  was	  captured	   to	  a	   level	  of	  120	  RU.	  After	  252	  
recording	   association	   and	   dissociation	   sensograms	   of	   recombinant	   HA	   concentration	  253	  
series	  (0.625,	  1.25,	  2.5,	  5,	  and	  10	  nM	  for	  HA	  1,	  4	  and	  5,	  and	  5,	  10,	  20,	  40	  and	  80	  nM	  for	  254	  
HA	  3	  and	  12,	   respectively)	  at	  a	   flow-­‐rate	  of	  30	  µl/min,	  data	  was	   fitted	  to	  a	  simple	  1:1	  255	  
binding	   model	   (T100	   Evaluation	   Software,	   Biacore)	   and	   the	   ka,	   kd	   and	   KD	   constants	  256	  
calculated.	  257	  
Crystallization	  and	  structure	  determination	  of	  Fab	  3.1-­‐Sc1918/H1	  HA	  258	  
For	   Fab/HA	   complex	   formation,	  mAb	  3.1	   Fab	  was	   added	   to	   Sc1918/H1	  HA	   in	   a	  molar	  259	  
ratio	  of	  ~3.2:1	  to	  saturate	  all	  of	  the	  mAb3.1	  binding	  sites	  on	  the	  HA	  trimer.	  The	  mixture	  260	  
was	  incubated	  overnight	  at	  4°C	  to	  allow	  complex	  formation.	  Saturated	  complexes	  were	  261	  
then	   purified	   from	   unbound	   Fab	   by	   gel	   filtration	   and	   concentrated	   to	   ~10	  mg/mL	   in	  262	  
10mM	  Tris-­‐HCl,	  pH	  8.0	  and	  50	  mM	  NaCl.	  Fab3.1-­‐Sc1918/H1	  HA	  crystals	  were	  grown	  by	  263	  
sitting	   drop	   vapor	   diffusion	   at	   20°C	   by	  mixing	   0.5	   µL	   of	   concentrated	   protein	   sample	  264	  
with	  0.5	  µL	  of	  mother	  liquor	  (15%	  PEG	  3350,	  0.1M	  magnesium	  sulfate,	  100mM	  Tris-­‐HCl	  265	  
pH	  7.5	  and	  crystals	  appeared	  after	  3	  days.	  The	  resulting	  crystals	  were	  cryoprotected	  by	  266	  
soaking	   the	   crystals	   in	   well	   solution	   supplemented	   with	   increasing	   concentrations	   of	  267	  
ethylene	  glycol	  (5%	  steps,	  5	  min/step),	  to	  a	  final	  concentration	  of	  35%,	  then	  flash	  cooled	  268	  
and	  stored	  in	  liquid	  nitrogen.	  	  269	  
Diffraction	   data	   were	   collected	   at	   the	   Canadian	   Light	   Source	   (CLS).	   The	   data	   were	  270	  
indexed	   in	   space	   group	  R3,	   scaled	   and	   integrated	  using	  Denzo	   and	   Scalepack	   through	  271	  
the	   HKL2000	   package	   (HKL	   Research).	   Data	   collection	   and	   refinement	   statistics	   are	  272	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summarized	   in	  Suppl.	  Table	  4.	   	  The	  structure	  was	  solved	  by	  molecular	   replacement	   to	  273	  
2.9	   Å	   resolution	   using	   Phaser	   (39).	   Rigid	   body	   refinement,	   simulated	   annealing	   and	  274	  
restrained	  refinement	  (including	  TLS	  refinement,	  one	  for	  each	  Ig	  domain)	  were	  carried	  275	  
out	  in	  Refmac	  (40).	  Between	  rounds	  of	  refinement,	  the	  model	  was	  rebuilt	  and	  adjusted	  276	  
using	  Coot	  (41).	  277	  
Crystallization	  and	  structure	  determination	  of	  mAb	  3.1	  Fab	  278	  
The	  methods	  used	  to	  determine	  the	  mAb	  3.1	  Fab	  structure	  were	  very	  similar	  to	  those	  279	  
described	  above.	  Briefly,	  Fab	  3.1	  at	  15mg/ml	  in	  10mM	  Tris,	  pH	  8.0	  and	  50	  mM	  NaCl	  was	  280	  
subjected,	   after	   gel	   filtration,	   to	   robotic	   crystallization	   trials	   using	   the	   Rigaku	  281	  
Crystalmation	  robotic	  system	  at	  the	  JCSG.	  Several	  hits	  were	  obtained.	  The	  crystals	  used	  282	  
for	   data	   collection	   were	   grown	   by	   the	   sitting	   drop	   vapor	   diffusion	   method	   with	   a	  283	  
reservoir	  solution	  (1	  ml)	  containing	  0.2	  M	  calcium	  acetate,	  10%	  PEG	  8000	  and	  100	  mM	  284	  
Tris	   pH	   7.0.	   The	   resulting	   crystals	   were	   cryoprotected	   by	   soaking	   in	   well	   solution	  285	  
supplemented	  with	  35%	  ethylene	  glycol,	  then	  flash	  cooled	  and	  stored	  in	  liquid	  nitrogen	  286	  
until	  data	  collection.	  	  287	  
The	   Fab	   3.1	   dataset	   was	   collected	   to	   2.7	   Å	   resolution	   at	   APS	   GM/CA-­‐CAT	   23ID-­‐B	  288	  
beamline.	  Data	   collection	   and	   refinement	   statistics	   are	   summarized	   in	   Suppl.	   Table	   4.	  289	  
The	  structure	  was	  solved	  using	  the	  same	  strategies	  as	  described	  above	  for	  the	  Fab	  3.1-­‐290	  
Sc1918/H1	  complex.	  291	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Structural	  analysis	  292	  
Hydrogen	  bonds	  and	  van	  der	  Waals’	  contacts	  between	  Fab	  3.1	  and	  Sc1918/H1	  HA	  were	  293	  
calculated	   using	   HBPLUS	   and	   CONTACSYM,	   respectively	   (42,	   43).	   Surface	   area	   buried	  294	  
upon	  Fab	  binding	  to	  the	  HA	  was	  calculated	  with	  MS	  (44).	  MacPyMol	  (DeLano	  Scientific)	  295	  
was	  used	   to	   render	   structure	   figures	  and	   for	   general	  manipulations.	  Kabat	  numbering	  296	  
was	  applied	  to	  the	  coordinates	  using	  the	  Abnum	  server	  (45).	  The	  final	  coordinates	  were	  297	  
validated	  using	  the	  JCSG	  quality	  control	  server	  (v2.7),	  which	  includes	  MolProbity	  (46).	  	  298	  
Results	  299	  
Isolation	  and	  characterization	  of	  monoclonal	  antibody	  3.1	  300	  
Using	  RNA	  isolated	  from	  mature	  B	  cells	  of	  a	  healthy	  donor,	  a	  Fab	  phage	  display	  library	  301	  
was	   prepared	   and	   used	   for	   panning	   against	   trimeric	   baculovirus-­‐expressed	   HA	   from	  302	  
A/Japan/305/1957(H2N2)	   (6)	   that	  was	   reversibly	   immobilized	  on	  magnetic	   beads.	   The	  303	  
H2	  subtype	  was	  chosen	  for	  two	  reasons:	  first,	  antibody	  epitope	  mapping	  suggested	  that	  304	  
there	  is	  an	  antigenic	  site	  in	  the	  stem	  of	  this	  subtype	  protein	  that	  is	  not	  present	  in	  other	  305	  
human	  HA	  subtypes.	  (5,	  6).	  Second,	  the	  donor	  of	  the	  B	  cells	  used	  for	  the	  preparation	  of	  306	  
the	  phage	   library	  was	  born	   in	  1976	  and	  should	   therefore	  be	   immunologically	  naïve	   to	  307	  
the	   H2	   subtype	   that	   ceased	   circulating	   in	   humans	   in	   1967.	   Consequently,	   H2-­‐binding	  308	  
antibodies	  isolated	  from	  this	  donor	  are	  by	  definition	  bona	  fide	  natural	  heterosubtypic	  or	  309	  
cross-­‐reactive	   antibodies	   that	   arose	   from	   novel	   heavy-­‐light-­‐chain	   combinations	  310	  
generated	  during	  the	  phage	  display	  library	  preparation.	  311	  
16	  
	  
After	  four	  rounds	  of	  panning,	  13	  clones	  were	  selected	  for	  further	  characterization.	  Nine	  312	  
out	  of	  thirteen	  clones	  possessed	  the	  same	  heavy	  chain	  paired	  to	  different	  light	  chains	  313	  
with	  the	  remaining	  four	  only	  differing	  in	  a	  maximum	  of	  four	  nucleotides	  from	  the	  314	  
consensus	  sequence.	  The	  light	  chain	  repertoire	  was	  more	  diverse	  and	  included	  7	  distinct	  315	  
kappa	  and	  3	  distinct	  lambda	  light	  chains	  (Supp.	  Table	  1).	  While	  the	  common	  heavy	  chain	  316	  
of	  all	  clones	  shared	  the	  very	  same	  VDJ-­‐gene	  segment	  usage	  as	  mAb	  FI6	  (IGHV3-­‐30,	  317	  
IGHD3-­‐9,	  IGHJ4*01;7),	  none	  of	  the	  light	  chains	  isolated	  in	  this	  experiment	  displayed	  the	  318	  
same	  IGKV4-­‐1	  x	  IGKJ1	  genotype	  of	  the	  FI6	  light	  chain	  (Suppl.	  Table	  1).	  Since	  at	  that	  time	  319	  
the	  mutations	  that	  enable	  FI6	  to	  recognize	  also	  HA	  subtypes	  from	  phylogenetic	  group	  2	  320	  
were	  not	  known,	  we	  randomly	  selected	  a	  representative	  clone	  based	  on	  phage-­‐ELISA	  321	  
data	  using	  H2	  as	  coating	  antigen.	  This	  clone,	  referred	  to	  as	  mAb	  3.1,	  expressed	  the	  322	  
common	  heavy	  chain	  paired	  to	  an	  IGκV1-­‐12	  x	  IGκJ4*01	  light	  chain.	  Its	  light	  chain	  did	  not	  323	  
display	  somatic	  hypermutation,	  and	  only	  nucleotide	  replacements	  in	  FR1	  that	  caused	  324	  
amino	  acid	  residues	  at	  positions	  1	  and	  2	  (IMGT	  numbering)	  to	  differ	  from	  the	  reference	  325	  
alleles	  deposited	  at	  IMGT	  were	  found.	  However,	  these	  mutations	  are	  most	  likely	  an	  326	  
artifact	  arising	  from	  serial	  PCR	  amplification	  required	  for	  the	  preparation	  of	  a	  phage	  327	  
display	  library	  (36).	  	  328	  
Specificity	  of	  mAb	  3.1	  329	  
In	   enzyme-­‐linked	   immunosorbent	   assays	   (ELISA),	   mAb	   3.1	   was	   found	   to	   bind	   to	  330	  
recombinant	   HA	   proteins	   from	   A/Puerto	   Rico/8/1934(H1N1)	   and	  331	  
A/Japan/305/1957(H2N2)	   group	   1	   influenza	   A	   viruses,	   but	   failed	   to	   bind	   to	  332	  
A/Victoria/3/1975(H3N2)	  and	  A/Fowl	  Plague/Bratislava/1979(H7N7)	  group	  2	  influenza	  A	  333	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viruses.	  mAb	  3.1	  was	  also	   found	   to	  bind	   to	   recombinant	  HA	   from	   recently	  discovered	  334	  
H18	  from	  A/flat-­‐faced	  bat/Peru/033/10	  (H18N1),	  but	  failed	  to	  bind	  to	  H17	  from	  A/little	  335	  
yellow	  shouldered	  bat/Guatemala/164/09	  (H17N10)	  (data	  not	  shown).	  336	  
Using	   bio-­‐layer	   interferometry	   (BLI),	   Fab	   fragments	   of	   mAb3.1	   also	   bound	   to	  337	  
biotinylated	   HA	   from	   A/duck/Alberta/345/1976(H1N1),	   A/USSR/90/1977(H1N1),	  338	  
A/Beijing/262/1995(H1N1),	   A/Solomon	   Islands/3/2006(H1N1),	  339	  
A/Japan/305/1957(H2N2),	   A/Adachi/2/1957(H2N2),	   A/Vietnam/1203/2004(H5N1),	  340	  
A/turkey/Massachusetts/3740/1965(H6N2).	   No	   binding	   was	   found	   by	   ELISA	   or	   BLI	   to	  341	  
A/duck/Alberta/60/1976(H12N5),	   A/gull/Maryland/704/1977(H13N6),	   A/black-­‐headed	  342	  
gull/Sweden/4/99(H16N3),	   A/duck/Ukraine/1/1963(H3N8),	   A/Hong	  343	  
Kong/1/1968(H3N2),	   A/duck/Czechoslovakia/1956(H4N6),	  344	  
A/Netherlands/219/2003(H7N7),	   A/Fowl	   plague/Bratislava/1979(H7N7),	  345	  
A/chicken/Germany/N/1949(H10N7),	   A/mallard/Astrakhan/263/1982(H14N5),	  346	  
A/shearwater/W.	   Australia/2576/79(H15N9).	   Thus,	   mAb	   3.1	   bound	   HA	   proteins	   from	  347	  
phylogenetic	  group	  1	  but	  did	  not	  bind	  HA	  proteins	  belonging	   to	  phylogenetic	  group	  2	  348	  
(Supp.	  Table	  2).	  	  349	  
The	   antiviral	   activity	   of	   mAb	   3.1	   against	   at	   least	   one	   representative	   isolate	   from	  350	  
subtypes	   H1	   through	   H15	   was	   tested.	   In	   hemagglutination	   inhibition	   assays,	   no	  351	  
inhibition	   of	   A/Puerto	   Rico/8/34(H1N1)	   was	   found	   indicating	   that	   mAb	   3.1	   does	   not	  352	  
interfere	  with	   receptor	  binding	   (data	  not	   shown).	  Since	  pseudotyped	   influenza	  viruses	  353	  
were	   described	   to	   be	   more	   easily	   neutralized	   than	   live	   virus	   (31),	   all	   neutralization	  354	  
assays	   were	   performed	   with	   viable	   influenza	   viruses.	   To	   this	   end,	   we	   established	   a	  355	  
18	  
	  
robust	   fluorescence-­‐based	  neutralization	   assay	   that	   employed	  105	   infectious	  units	   per	  356	  
well,	   corresponding	   to	   a	  multiplicity	   of	   infection	   of	   2	   to	   3.	   Using	   this	   assay,	  mAb	   3.1	  357	  
neutralized	   viruses	   of	   the	   H1,	   H2,	   H5,	   H6	   subtypes	   at	   half-­‐maximal	   inhibitory	  358	  
concentrations	   in	   the	  µg/ml	   range	   (Figure	  1).	  Thus,	   like	  most	  VH1-­‐69-­‐encoded	  and	   the	  359	  
germline-­‐reverted	   variants	   of	   FI6,	   mAb	   3.1	   was	   only	   able	   to	   neutralize	   isolates	   from	  360	  
phylogenetic	   group	   1.	   However,	   within	   phylogenetic	   group	   1,	   it	   did	   not	   neutralize	  361	  
isolates	   from	   the	   H1b	   clade	   that	   includes	   the	   H11,	   H13,	   and	   H16	   subtypes,	   and	   it	  362	  
displayed	  very	  low	  antiviral	  activity	  against	  isolates	  from	  the	  H9	  clade	  (i.e.	  H8,	  H9,	  H12)	  363	  
at	  concentrations	  over	  20µg,	  if	  at	  all.	  	  364	  
The	  main	  differences	  in	  the	  stem	  epitope	  between	  the	  H1b	  and	  the	  remaining	  clades	  are	  365	  
a	   glycosylation	   site	   at	   position	   291	   of	   HA1,	   and	   the	   lack	   of	   a	   proline	   at	   position	   293.	  366	  
These	  may	   interfere	  with	   interaction	  of	  HA1	  with	   FR3	   residues	   of	  mAb	  3.1.	  However,	  367	  
since	  the	  only	  exception	  with	  this	   respect,	  subtype	  H6,	   is	  well	   recognized	  by	  mAb	  3.1,	  368	  
these	  differences	  alone	  are	  unlikely	  to	  be	  the	  sole	  reason	  for	  the	  different	  recognition	  369	  
by	   mAb3.1.	   Indeed,	   removal	   of	   the	   glycosylation	   site	   at	   position	   291	   in	   the	  370	  
hemagglutinin	   of	   A/duck/Memphis/546/1974(H11N9)	   and	   reassortment	   into	   A/Puerto	  371	  
Rico/8/34(H1N1)	   did	   not	   improve	   3.1-­‐mediatied	   neutralization	   sensitivity	   of	   the	  372	  
resulting	   reassortant	   virus	   (Figure	   2).	   However,	   if	   removal	   of	   the	   glycosylation	   site	   at	  373	  
position	  291	  was	  accompanied	  by	  the	  introduction	  of	  a	  Pro	  at	  position	  293,	  the	  resulting	  374	  
virus	   became	   partially	   sensitive	   to	   neutralization	   by	   mAb3.1.	   In	   contrast,	   neither	   the	  375	  
introduction	  of	  a	  glycosylation	  site	  at	  position	  291	  or	  removal	  of	  the	  proline	  at	  position	  376	  
293	   of	   the	   hemagglutinin	   from	   A/Puerto	   Rico/8/34(H1N1)	   altered	   its	   neutralization	  377	  
19	  
	  
sensitivity.	   Thus,	   depending	   on	   the	   structural	   context,	   these	   two	   residues	   impact	   the	  378	  
neutralization	  sensitivity	  for	  antibodies	  binding	  to	  this	  epitope.	  379	  
In	  vivo	  protection	  380	  
Passively	   immunization	   with	   mAb	   3.1	   protects	   mice	   from	   a	   lethal	   challenge	   with	  381	  
A/Puerto	  Rico/8/34(H1N1).	  As	   depicted	   in	   Figure	   3,	   all	  mice	  were	  protected	   against	   a	  382	  
lethal	  challenge	  with	  2	  LD50	  of	  A/Puerto	  Rico/8/34(H1N1)	  when	  10mg/kg	  mAb3.1	  were	  383	  
transfused	   24h	   before	   infection.	   Also	   at	   3mg/kg,	   8	   out	   of	   10	   mice	   were	   protected	  384	  
against	  the	  same	  dose	  of	  virus	  in	  two	  independent	  experiments	  (Figure	  3).	  Weight	  loss	  385	  
in	   infected	   animals	   was	   considerably	   attenuated	   at	   10mg/kg	   with	   9	   out	   10	   animals	  386	  
losing	  less	  than	  15%	  of	  their	  initial	  body	  weight.	  Also	  at	  3mg/kg,	  7	  out	  of	  the	  8	  surviving	  387	  
mice	  lost	  less	  than	  15%	  of	  the	  initial	  body	  weight	  during	  the	  course	  of	  the	  infection.	  In	  388	  
contrast,	   the	  weight	  of	  all	  control	  animals	  dropped	  below	  15%	  already	  at	  day	  4.	  Thus,	  389	  
the	   in	   vivo	   protective	   capacity	   of	   mAb3.1	   was	   comparable	   to	   FI6,	   another	   VH3-­‐30	  390	  
encoded	   monoclonal	   antibody	   and	   in	   the	   same	   range	   as	   all	   other	   heterosubtypic	  391	  
antibodies	  described.	  In	  accordance	  to	  3R	  recommendations	  of	  the	  Swiss	  animal	  welfare	  392	  
authorities,	  we	  did	  not	  perform	  further	  in	  vivo	  experiments	  with	  other	  strains,	  as	  we	  did	  393	  
not	  expect	  any	  new	  insights	  (or	  surprises)	  from	  a	  replication	  of	  these	  experiments.	  394	  
Crystal	  structure	  of	  mAb	  3.1	  395	  
To	  analyze	  the	  molecular	  interaction	  with	  HA,	  the	  crystal	  structure	  of	  the	  Fab	  fragment	  396	  
of	  mAb	  3.1	  in	  complex	  with	  soluble	  HA	  from	  a	  pandemic	  H1N1	  influenza	  virus	  A/South	  397	  
Carolina/1/18(H1N1)	  was	  solved	  at	  2.9	  Å	  resolution	  (Figure	  4).	  Not	  surprisingly,	  mAb	  3.1	  398	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recognizes	   the	   same	   hydrophobic	   groove	   in	   the	   stem	   as	   other	   VH3-­‐30	   or	   VH1-­‐69-­‐399	  
encoded	  antibodies.	  The	  epitope	  consists	  of	  residues	  from	  the	  N-­‐	  and	  C-­‐terminal	  regions	  400	  
of	  HA1	  (38,	  40-­‐42,	  289-­‐293,	  318),	  and	  the	  N-­‐terminal	  portion	  of	  HA2	  (18-­‐21,	  38,	  41,	  42,	  401	  
45,	  49,	  52,	  53,	  56),	  including	  helix	  A	  (Figure	  4B).	  Fab	  3.1	  buries	  a	  total	  of	  ~1333	  Å2	  at	  the	  402	  
interface	   with	   HA	   (686	   Å2	   for	   HA	   and	   647	   Å2	   for	   Fab)	   and	   almost	   exclusively	   uses	  403	  
residues	  of	  the	  heavy	  chain	  (96%	  of	  the	  Fab	  buried	  surface	  area)	  for	  these	  interactions	  404	  
(Figure	  4A).	  The	  angle	  of	  approach	  of	  Fab	  3.1	  is	  similar	  to	  murine	  antibody	  C179	  and	  FI6,	  405	  
despite	  different	  binding	  interactions	  (21,	  23).	  The	  VH	  domain	  binds	  using	  a	  combination	  406	  
of	   three	   loops,	   including	   HCDRs	   1	   and	   3,	   and	   the	   tip	   of	   FR3	   (Figure	   4C).	   HCDR1	   and	  407	  
HCDR3	   account	   for	   85%	   of	   the	   van	   der	  Waals	   contacts	   between	   Fab	   and	   HA,	   where	  408	  
Phe27	   (HCDR1),	   Tyr99	   and	   Phe100	   (HCDR3)	   make	   many	   of	   the	   key	   hydrophobic	  409	  
interactions	  (~50%	  of	  van	  der	  Waals).	  Corresponding	  HCDR3	  interactions	  were	  observed	  410	  
in	  the	  HA	  complexes	  with	  FI6	  and	  C179,	  where	  both	  insert	  the	  same	  two	  aromatic	  side	  411	  
chains	  from	  their	  HCDR3	  loops	  (Tyr99mAb3.1,	  Tyr98C179	  and	  Tyr100CFI6;	  and	  Phe100mAb3.1,	  412	  
Phe99C179	   and	   Phe100DFI6)	   into	   the	   hydrophobic	   groove	   (Figure	   4C).	   As	   in	   previously	  413	  
described	   antibodies	   (CR62621,	   F10,	   C179)	   or	   designed	   proteins	   (HB36	   and	   F-­‐HB80.4)	  414	  
that	  are	  specific	  to	  group	  1	  influenza	  A	  viruses,	  mAb	  3.1	  make	  a	  similar	  interaction	  with	  415	  
Trp21	   where	   Phe100	   at	   the	   tip	   of	   HCDR3	   is	   in	   a	   remarkably	   similar	   position	   and	  416	  
orientation	  to	  the	  aromatics	   in	  the	  other	  antibodies	  and	  designed	  HA	  binding	  proteins	  417	  
(Figure	  4A)	  (21,	  23,	  26,	  31,	  47,	  48).	  	  418	  
In	   addition	   to	   the	  HCDR-­‐mediated	   interactions,	   residues	   74	   through	   76	   of	   framework	  419	  
region	  3	  (FR3)	  contact	  Asn289	  and	  Ser291	  of	  HA1.	  Like	  FI6,	  mAb	  3.1	  also	  employs	  LCDR1	  420	  
21	  
	  
to	   contact	   HA2.	   However,	   in	   the	   case	   of	  mAb	   3.1,	   these	   contacts	   do	   not	   involve	   the	  421	  
fusion	  peptide	  but	  are	  formed	  by	  van	  der	  Waals	   interactions	  between	  Gln38	  at	  the	  N-­‐422	  
terminal	  end	  of	  the	  A	  helix	  and	  Trp	  32	  of	  the	  light	  chain.	  In	  contrast	  to	  FI6,	  where	  a	  long	  423	  
HCDR3	   solely	   mediates	   contacts	   with	   the	   hydrophobic	   grove,	   mAb31	   employs	   a	  424	  
combination	   of	   HCDR	   H1	   and	   H3	   to	   contact	   the	   HA	   (Figure	   4C).	   In	   this	   way,	   the	  425	  
membrane-­‐proximal	  contacts	  on	  the	  HA	  are	  made	  by	  HCDR3,	  while	  residues	  of	  HCDR1	  426	  
provide	  the	  apical	  interactions.	  427	  
Of	  note,	  it	  was	  found	  that	  mAb3.1	  closely	  mimicked	  some	  of	  the	  interactions	  in	  the	  de	  428	  
novo	  in	  silicio	  designed	  and	  affinity-­‐matured	  synthetic	  protein	  HB36.3.	  In	  particular,	  the	  429	  
α-­‐helical	   structure	   of	   HCDR1	   is	   reminiscent	   of	   HB36.3’s	   recognition	   helix	   with	   very	  430	  
similar	  hydrophobic	  interactions	  mediated	  by	  Phe	  side	  chains	  at	  positions	  27	  and	  100	  of	  431	  
mAb3.1	   and	   positions	   49	   and	   61	   of	   HP36.3	   (Figure	   4C).	   Comparison	   with	   the	   crystal	  432	  
structure	  for	  unbound	  mAb	  3.1	  revealed	  that	  a	  twisting	  of	  HCDR1	  Phe27	  in	  the	  bound	  433	  
versus	   free	   configuration	  most	   likely	   triggers	   this	  α-­‐helix	   formation	   (Figure	   4D).	   The	  434	  
striking	  similarities	  with	  HB36.3	  demonstrate	  nicely	  that	   in	  silicio	  designed	  and	   in	  vitro	  435	  
maturated	  synthetic	  proteins	  can	  foretell	  naturally	  selected	  antibody	  binding	  mode	  and	  436	  
interactions.	  	  437	  
In	  contrast	  to	  most	  other	  heterosubtypic	  antibodies	  where	  the	  light	  chain	  was	  described	  438	  
not	   to	   be	   essential	   for	   binding,	   FI6	   possesses	   two	   residues	   (Phe27d	   and	   Arg93)	   in	   its	  439	  
light	  chain	  whose	  reversion	  to	  germline-­‐encoded	  serines	  drastically	  reduced	  the	  ability	  440	  
to	  bind	  to	  HA	  proteins	  of	  phylogenetic	  group	  2	  HA,	  even	  when	   introduced	   individually	  441	  
(23).	   However,	   when	   the	   FI6	   light	   chain	   was	   paired	  with	   the	   heavy	   chain	   of	   3.1,	   the	  442	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hybrid	  antibody	  displayed	   the	  binding	  and	  neutralization	  profile	  of	  mAb	  3.1,	   in	   that	   it	  443	  
failed	   to	  bind	   to	   recombinant	  H3,	  H7,	  and	  H12	  and	  was	  not	  able	   to	  neutralize	  viruses	  444	  
belonging	   to	   phylogenetic	   group	   2	   (data	   not	   shown).	   These	   results	   indicate	   that	   the	  445	  
beneficial	  impact	  of	  these	  light-­‐chain	  residues	  is	  specific	  to	  FI6.	  446	  
Discussion	  447	  
We	  isolated	  a	  VH3-­‐30	  encoded	  heterosubtypic	  monoclonal	  antibody	  that	  can	  neutralize	  448	  
viruses	   from	  the	  H1a	  clade	  very	  well	  with	   low	  neutralizing	  activity	  also	  against	   the	  H9	  449	  
subtype.	  For	  its	  isolation,	  a	  novel	  panning	  strategy	  was	  performed	  that	  took	  advantage	  450	  
of	  three	  rational	  designs.	  First,	  by	  using	  an	  HA	  subtype	  (H2)	  to	  which	  the	  donor	  is	  naïve	  451	  
as	  the	  selecting	  antigen,	  all	  antibodies	   isolated	  are	  bona-­‐fide	  cross-­‐reactive.	  Second	  by	  452	  
tethering	  HA	  trimers	   in	  an	  upside-­‐down	  orientation	  to	  beads,	   the	  apical	   strain-­‐specific	  453	  
epitopes	   were	   occluded,	   while	   the	   conserved	   stem-­‐specific	   epitopes	   became	  454	  
prominently	  exposed.	  Third,	  using	  monoclonal	  antibodies	  for	  classical	  epitope	  mapping,	  455	  
the	  H2	  subtype	  was	  found	  to	  have	  an	  additional	  antigenic	  site	   ‘II-­‐A’	   in	  the	  stem	  of	  the	  456	  
HA	  protein	  that	  has	  not	  been	  described	  for	  other	  subtypes	  (5,	  22).	  Also,	  the	  first	  known	  457	  
monoclonal	  heterosubtypic	  antibody	  C179	  was	   isolated	   from	  mice	   immunized	  with	  H2	  458	  
(31).	  We	  therefore	  assumed	  that	  H2	  may	  be	  a	  particular	  good	  subtype	  for	  the	  isolation	  459	  
of	   stem-­‐specific	   antibodies.	   Indeed,	   the	   panning	   readily	   produced	   numerous	  460	  
heterosubtypic	   antibodies	   confirming	   that	   the	   strategy	   works.	   However,	   as	   we	   have	  461	  
been	   able	   to	   isolate	   much	   broader	   heterosubtypic	   antibodies	   by	   panning	   against	   a	  462	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different	  inverted	  HA	  subtype,	  we	  do	  not	  believe	  that	  H2	  is	  exceptionally	  well-­‐suited	  for	  463	  
this	  purpose.	  	  464	  
As	  with	  all	  phage	  display	  experiments,	  it	  cannot	  be	  conclusively	  deduced	  that	  antibodies	  465	  
isolated	   using	   this	   strategy	   are	   in	   the	   same	   heavy-­‐light	   chain	   composition	   as	   in	   the	  466	  
natural	   repertoire	   of	   the	   donor.	   However,	   as	   stem-­‐specific,	   heterosubtypic	   antibodies	  467	  
primarily	  contact	  their	  epitope	  with	  residues	  of	  the	  heavy	  chain,	  especially	  for	  the	  VH1-­‐468	  
69	  antibodies,	  	  we	  believe	  that,	  in	  this	  case,	  this	  issue	  is	  of	  minor	  impact.	  	  469	  
The	  mAb	  3.1	  contacts	  a	   similar	  epitope	   in	   the	  stem	  of	   the	  HA	  as	  all	  other	  VH3-­‐30	  and	  470	  
VH1-­‐69	  encoded	  antibodies.	  It	  primarily	  involves	  residues	  of	  the	  heavy	  chain	  for	  binding	  471	  
to	  the	  hydrophobic	  groove	  in	  this	  epitope.	  Our	  finding,	  together	  with	  recently	  published	  472	  
heterosubtypic	   antibodies	   from	   a	   donor	   vaccinated	   with	   pandemic	   H1	   hemagglutinin	  473	  
(29),	   reinforces	   the	   predominance	   of	   VH1-­‐69	   and	   VH3-­‐30-­‐encoded	   antibodies	   in	   the	  474	  
human	  repertoire	  of	  influenza	  heterosubtypic	  antibodies.	  For	  mAb3.1,	  only	  4	  out	  of	  10	  475	  
somatically	  hypermutated	  residues	  of	  the	  VH	  gene	  are	  actually	  involved	  in	  the	  binding	  of	  476	  
the	   HA	   protein,	   suggesting	   that	   the	   majority	   of	   the	   contact	   residues	   are	   already	  477	  
satisfactorily	   encoded	   in	   the	   VH3-­‐30	   germline	   gene.	   However,	   in	   contrast	   to	   FI6	   that	  478	  
primarily	  employs	  HCDR3,	  and	  to	  a	  lesser	  extent	  LCDR1,	  mAb	  3.1	  uses	  a	  combination	  of	  479	  
both	  HCDR1	  and	  HCDR3	  to	  contact	   the	  hydrophobic	  groove.	  Thus,	  diversity	  generated	  480	  
by	  recombination	  of	  the	  CDR	  regions	  appears	  to	  be	  of	  great	  importance;	  in	  FI6,	  residues	  481	  
contacting	   the	   conserved	   epitope	   almost	   primarily	   arise	   from	   the	   antibody	   gene	  482	  
rearrangement.	   Also	   in	   mAb	   3.1,	   46%	   of	   the	   interactions	   between	   mAb	   3.1	   and	   HA	  483	  
involves	  residues	  from	  HCDR3.	  Rearrangement	  of	  both	  VH3-­‐30-­‐endcoded	  heterosubtypic	  484	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antibodies	   led	   to	  an	  extensive	  addition	  of	  non-­‐templated	  N-­‐nucleotides.	   For	  mAb	  3.1,	  485	  
there	   is	  no	  addition	  of	  N1	  nucleotides,	  but	   the	  N2	   region	   contains	  17	  nucleotides	   (5'-­‐486	  
tcataaggggcattatg-­‐3')	   encoding	   for	   7	   aa	   (FIRIGIM),	   two	   of	   which	   (F100,	   R100B)	  487	  
contribute	   to	   binding.	   In	   the	   case	   of	   FI6,	   the	   N-­‐nucleotide	   additions	   are	   even	   more	  488	  
extensive	  with	  a	  total	  of	  32	  non-­‐templated	  nucleotides,	  22	  nt	  of	  which	  are	  N1	  (5’-­‐c	  tcc	  489	  
caa	   ctg	   cga	   tca	   ctc	   ctc-­‐3’)	   and	   10	   are	   N2	   (5’-­‐cc	   cag	   gga	   tat-­‐3’)	   nucleotides	   that	   also	  490	  
contain	  key	  residues	  for	  heterosubtypic	  binding	  (L98,	  R99).	  Both	  antibodies	  use	  the	  D3-­‐9	  491	  
segment	   that	   provides	   these	   antibodies	  with	   two	   essential	   hydrophobic	   residues	   that	  492	  
insert	   into	   the	   HA	   hydrophobic	   groove.	   Thus,	   the	   VH3-­‐30	   germline	   gene	   appears	   to	  493	  
provide	  good	  framework	  for	  heterosubtypic	  antibodies	  as	  it	  provides	  an	  HCDR1	  that	  can	  494	  
be	   used	   to	   contact	   the	   apical	   region	   of	   the	   conserved	   stem	   epitope,	   in	   particular	   if	  495	  
joined	  to	  D3-­‐9,	  or	  other	  D	  regions	  capable	  of	  providing	  additional	  hydrophobic	  residues.	  	  496	  
Like	  most	  other	  hmAbs,	  mAb	  3.1	  can	  protect	  mice	  against	  a	  lethal	  challenge	  with,	  in	  this	  497	  
case,	   A/Puerto	   Rico/8/34(H1N1)	   virus.	   However,	   from	   our	   data,	   we	   cannot	   conclude	  498	  
whether	  this	  protection	  is	  directly	  mediated	  by	  its	  neutralizing	  activity,	  or	  whether	  other	  499	  
effector	   mechanisms	   such	   as	   complement	   activation	   or	   Fc-­‐receptor	   mediated	  500	  
cytotoxicity	  are	  of	  importance.	  As	  it	  has	  been	  shown	  recently	  that	  Fc-­‐γ	  receptor	  binding	  501	  
is	  of	  importance	  for	  protection	  of	  mice	  by	  HA	  stem-­‐specific	  antibodies,	  we	  assume	  that	  502	  
the	   mAb	   3.1	   protection	   at	   least	   partially	   relies	   on	   antibody-­‐mediated	   cellular	  503	  
cytotoxicity	  (49)	  504	  
So	  far,	  the	  antigenic	  particularity	  of	  the	  H1b	  clade	  has	  been	  underappreciated.	  Even	  the	  505	  
broadest	   antibody	   described	   so	   far,	   CR9114	   did	   not	   neutralize	   an	  H11	   isolate	   despite	  506	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good	   binding	   to	   recombinant	   H13	   and	   H16	   HA	   proteins	   in	   ELISA	   (25).	   As	   depicted	   in	  507	  
Figure	  2,	   the	  C-­‐terminal	   region	  of	  HA1	  of	   the	  H11,	  H13	  and	  H16	  subtypes	  differs	   from	  508	  
the	  other	  members	  of	  phylogenetic	  group	  1	  (except	  H6)	  by	  the	  presence	  of	  a	  N-­‐linked	  509	  
glycosylation	  site	  at	  position	  291	  and	  the	  lack	  of	  a	  proline	  at	  position	  293.	  The	  proximity	  510	  
of	   these	   residues	   to	   contacting	   FR3-­‐residues	   of	   the	   antibody	   may	   affect	   binding	   of	  511	  
heterosubtypic	  antibodies.	  We	  also	  showed	  that	  removal	  of	  the	  glycosylation	  site	  by	  the	  512	  
introduction	  of	  a	  proline	  at	  position	  293	  made	  H11	  more	  susceptible	  to	  neutralization	  by	  513	  
mAb	  3.1.	  However,	  when	  the	  reciprocal	  mutations	  were	   introduced	   into	  H1,	  no	  effect	  514	  
was	   seen,	   indicating	   that,	   depending	   on	   the	   subtype,	   these	   mutations	   alone	   are	   not	  515	  
sufficient	  to	  affect	  the	  neutralization	  potency	  of	  heterosubtypic	  antibodies.	  	  516	  
However,	   further	   studies	   will	   be	   required	   to	   determine	   the	   general	   importance	   and	  517	  
impact	  of	  these	  two	  residues	  on	  broad	  reactivity	  of	  antibodies.	  	  518	  
Thus,	   isolation	   and	   characterization	   of	   a	   mAb	   3.1	   have	   enabled	   us	   to	   gain	   a	   better	  519	  
insight	   into	  the	  molecular	  requirements	  for	  binding	  to	  the	  highly	  conserved	  epitope	   in	  520	  
the	   stem	   of	   the	   HA	   protein.	   Moreover,	   this	   study	   provided	   structural	   evidence	   that	  521	  
binding	   of	   in	   silico	   and	   in	   vitro	   selected	   artificial	   antigens	   closely	   resemble	   that	   of	  522	  
naturally	  occurring	  antibodies.	   Together,	   this	   knowledge	  helps	  advance	  understanding	  523	  
of	   heterosubtypic	   binding	   to	   influenza	   HA	   and	   may	   aid	   in	   development	   of	   more	  524	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Figure	  Legends	  708	  
Figure	  1.	  Neutralizing	  activity	  of	  mAb	  3.1.	  Half-­‐maximal	  neutralizing	  titers	  (IC50)	  of	  mAb	  709	  
3.1	  to	  19	  viruses	  from	  15	  subtypes.	  Neutralization	  of	  H16	  was	  also	  assessed	  but	  failed	  to	  710	  
produce	  usable	  results	  due	  to	  the	  poor	  growth	  of	  the	  isolate	  on	  MDCK	  cells.	  Half-­‐711	  
maximal	  values	  above	  104	  or	  105	  ng/ml	  indicate	  no	  binding	  or	  neutralization,	  712	  
respectively.	  HIV-­‐1	  gp120-­‐specific	  mAb	  b12	  was	  used	  as	  a	  negative	  control	  in	  both	  713	  
experiments	  (αHIVA).	  A	  representative	  of	  at	  least	  two	  independent,	  consistent	  714	  
experiments	  [performed	  in	  duplicate	  (ELISA)	  or	  triplicate	  (neutralization)]	  is	  shown.	  715	  
Figure	  2.	  Neutralization	  sensitivity	  of	  wt	  and	  reassorted	  A/Puerto	  Rico/8/1934(H1N1)	  716	  
carrying	  wt	  or	  mutant	  H11	  hemagglutinin	  from	  A/duck/Memphis/546/1974	  (H11N9).	  717	  
To	  remove	  glycosylation	  at	  position	  291,	  aa	  293	  was	  mutated	  from	  threonine	  to	  alanine	  718	  
(deglyco	  291)	  or	  proline	  (pro	  293).	  The	  reciprocal	  mutations	  were	  introduced	  into	  H1	  as	  719	  
indicated	  in	  the	  lower	  left	  table.	  The	  lower	  right	  table	  displays	  an	  amino-­‐acid	  sequence	  720	  
alignment	  of	  the	  indicated	  isolates.	  Residues	  shaded	  in	  blue	  are	  contacted	  by	  mAb	  3.1,	  721	  
and	  asparagine	  residues	  shaded	  in	  red	  are	  potentially	  glycosylated.	  All	  isolates	  are	  722	  
grouped	  into	  the	  indicated	  clades	  as	  indicated	  by	  horizontal	  lines.	  723	  
Figure	  3.	  In	  vivo	  protection	  by	  passive	  immunization	  with	  mAb	  3.1.	  The	  indicated	  dose	  724	  
of	  antibody	  mAb	  or	  PBS	  were	  injected	  i.p.	  24h	  before	  intranasal	  infection	  with	  50	  LD50	  of	  725	  
A/Puerto	  Rico/8/34(H1N1).	  Body	  weight	  was	  monitored	  and	  mice	  were	  euthanized	  726	  
when	  their	  weight	  dropped	  below	  80%	  of	  the	  initial	  body	  weight.	  Data	  shown	  were	  727	  
pooled	  from	  two	  independent	  experiments.	  	  728	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Figure	  4.	  Crystal	  structure	  of	  Fab	  3.1	  bound	  to	  HA.	  (A)	  Overview	  of	  the	  antibody	  binding	  729	  
to	  the	  conserved	  epitope	  in	  the	  stem	  of	  the	  HA	  protein.	  (B)	  Fab	  3.1	  epitope,	  HA	  residues	  730	  
contacted	  by	  Fab	  3.1	  are	  represented	  as	  sticks.	  (C)	  Comparison	  of	  epitope	  recognition	  of	  731	  
Fab	  3.1	  with	  mAbs	  C179,	  FI6	  and	  CR9114	  (25),	  as	  well	  as	  designed	  synthetic	  binding	  732	  
proteins	  HB36.3	  (47)	  and	  F-­‐HB80.4	  (48).	  (D)	  Comparison	  of	  HCDR1	  free	  and	  in	  complex	  733	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Supplementary	  Tables	  1	  
	  2	  
mAb	   VH	   DH	   JH	   CDR	  H3	   VL	   JL	   CDR	  L3	  
3.1	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGKV1-­‐12*01,	  or	  
IGKV1-­‐12*02	  or	  
IGKV1D-­‐12*02	  
IGKJ4*01	   CQQANSFPLTF	  
3.2	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGLV2-­‐14*01	   IGLJ3*02	   CSSHTSSSTWVF	  
3.4	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGLV6-­‐57*01	   IGLJ7*01	   CQSYDNLNHAVF	  
3.5	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGKV3-­‐20*01	   IGKJ1*01	   CQQYGSSPRTF	  
3.7	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGLV3-­‐21*01	   IGLJ2*01,	  or	  
IGLJ3*01	  
CQVWDSHGDQVVF	  
3.8	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGKV3-­‐11*01	   IGKJ3*01	   CQQRSNWPVTF	  
3.9	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGLV1-­‐44*01	   n.a.	   n.a.	  
3.10	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGKV3-­‐20*01	   IGKJ1*01	   CQHYGASPKTF	  
3.11	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGLV1-­‐44*01	   IGLJ3*02	   CSSWDGGLSDWVF	  
3.12	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGKV3D-­‐20*01	   IGKJ1*01	   CQQYGSSPQTF	  
3.13	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGKV1-­‐33*01,	  or	  
IGKV1D-­‐33*01	  
IGKJ4*01	   CQQHDNLPLTF	  
3.14	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGKV3-­‐20*01	   IGKJ2*01	   CQQYGGSPPYTF	  
3.15	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGLV6-­‐57*01	   IGLJ3*02	   CQSYDSSNQWVF	  
3.16	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGLV2-­‐14*01	   IGLJ2*01,	  or	  
IGLJ3*01	  
CSSYTSSSTVVF	  
3.17	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGKV3-­‐20*01	   IGKJ4*01	   CQQYGSSPLTF	  
3.18	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGLV2-­‐14*01	   IGLJ2*01,	  or	  
IGLJ3*01	  
CSSYTSSSTVVF	  
3.48	   IGHV3-­‐30*04	   IGHD3-­‐9*01	   IGHJ4*01,	  or	  
IGHJ4*03	  
CARDLGGYFIRGIMDVW	   IGKV3-­‐20*01	   IGKJ1*01	   CQQYGSSPRTF	  
FI6	   IGHV3-­‐30*03,	  or	  
IGHV3-­‐30*18	  
IGHD3-­‐9*01	   IGHJ4*02	   CAKDSQLRSLLYFEWLSQGYFDPW	   IGKV4-­‐1*01	   IGKJ1*01	   CQQHYRTPPTF	  
Suppl.	  Table	  1.	  Genetic	  hallmarks	  of	  the	  antibodies	  isolated	  by	  panning	  a	  phage	  display	  3	  
library	  against	  recombinant	  H2	  protein	  with	  FI6	  included	  for	  reference.	  Assignment	  of	  4	  
the	  germline	  genes	  and	  CDRs	  were	  performed	  using	  the	  vquest	  tools	  provided	  at	  IMGT	  5	  
(http://imgt.org/IMGT_vquest/vquest?livret=0&Option=humanIg).	  6	  






type	   Strain	   KD	  (nM)	   HA1	   HA2	  
	   	   	   	   38	   40	   41	   42	   289	   290	   291	   292	   293	   318	   18	   19	   20	   21	   38	   41	   42	   45	   46	   48	   49	   52	   53	   56	  
1	   H1N1	   A/South	  Carolina/1/1918	   1	   H	   V	   N	   L	   N	   S	   S	   L	   P	   T	   I	   D	   G	   W	   Q	   T	   Q	   I	   D	   I	   T	   V	   N	   I	  
1	   H1N1	   A/duck/Alberta/345/1976	   1	   H	   V	   N	   L	   N	   S	   S	   L	   P	   I	   I	   D	   G	   W	   Q	   T	   Q	   I	   D	   I	   T	   V	   N	   I	  
1	   H1N1	   A/USSR/90/1977	   2.2	   H	   V	   N	   L	   N	   S	   S	   L	   P	   T	   I	   D	   G	   W	   Q	   T	   Q	   I	   N	   I	   T	   V	   N	   I	  
1	   H1N1	   A/Beijing/262/1995	   0.9	   H	   V	   N	   L	   N	   S	   S	   L	   P	   T	   M	   D	   G	   W	   Q	   T	   Q	   I	   N	   I	   T	   V	   N	   I	  
1	   H1N1	   A/Solomon	  Islands/3/2006	   2.8	   H	   V	   N	   L	   N	   S	   S	   L	   P	   T	   V	   D	   G	   W	   Q	   T	   Q	   I	   N	   I	   T	   V	   N	   I	  
1	   H2N2	   A/Japan/305/1957	   9.9	   H	   K	   D	   I	   N	   T	   T	   L	   P	   T	   V	   D	   G	   W	   K	   T	   Q	   F	   D	   I	   T	   V	   N	   I	  
1	   H2N2	   A/Adachi/2/1957	   10	   H	   K	   D	   I	   N	   T	   T	   L	   P	   T	   V	   D	   G	   W	   K	   T	   Q	   F	   D	   I	   T	   V	   N	   I	  
1	   H5N1	   A/Vietnam/1203/2004	   2	   H	   Q	   D	   I	   N	   S	   D	   M	   P	   T	   V	   D	   G	   W	   K	   T	   Q	   I	   D	   V	   T	   V	   N	   I	  
1	   H6N2	   A/turkey/Massachusetts/3740/1965	   25	   H	   V	   E	   L	   K	   T	   N	   K	   T	   T	   I	   D	   G	   W	   K	   T	   Q	   I	   D	   I	   T	   V	   N	   I	  
1	   H9N2	   A/turkey/Wisconsin/1/1966	   N.D	   H	   K	   E	   L	   N	   T	   T	   L	   P	   V	   V	   A	   G	   W	   K	   T	   Q	   I	   D	   I	   I	   V	   N	   I	  
1	   H12N5	   A/duck/Alberta/60/1976	   N.B	   Q	   E	   E	   L	   N	   T	   S	   K	   P	   T	   V	   A	   G	   W	   R	   T	   Q	   I	   D	   M	   Q	   L	   N	   I	  
1	   H13N6	   A/gull/Maryland/704/1977	   N.B	   S	   I	   D	   L	   N	   T	   N	   R	   T	   T	   I	   N	   G	   W	   K	   T	   Q	   I	   D	   I	   T	   I	   N	   I	  
1	   H16N3	   A/black-­‐headed	  gull/Sweden/4/99	   N.B	   S	   I	   D	   L	   N	   T	   N	   K	   T	   T	   I	   N	   G	   W	   K	   T	   Q	   I	   N	   I	   T	   I	   N	   I	  
2	   H3N2	   A/duck/Ukraine/1/1963	   N.B	   N	   T	   E	   L	   P	   N	   D	   K	   P	   T	   I	   D	   G	   W	   L	   T	   Q	   I	   D	   I	   N	   L	   N	   I	  
2	   H3N2	   A/Hong	  Kong/1/1968	   N.B	   N	   T	   E	   L	   P	   N	   D	   K	   P	   T	   I	   D	   G	   W	   L	   T	   Q	   I	   D	   I	   N	   L	   N	   I	  
2	   H4N6	   A/duck/Czechoslovakia/1956	   N.B	   T	   Q	   E	   L	   S	   T	   T	   K	   P	   T	   I	   D	   G	   W	   L	   T	   Q	   I	   D	   I	   N	   L	   N	   I	  
2	   H7N7	   A/Netherlands/219/2003	   N.B	   N	   T	   E	   T	   I	   S	   N	   L	   P	   T	   I	   D	   G	   W	   Y	   T	   Q	   I	   D	   I	   T	   L	   N	   I	  
2	   H10N7	   A/chicken/Germany/N/1949	   N.B	   N	   T	   E	   T	   N	   T	   K	   L	   P	   T	   V	   D	   G	   W	   Y	   T	   Q	   I	   D	   I	   T	   L	   N	   I	  
2	   H14N5	   A/mallard/Astrakhan/263/1982	   N.B	   S	   K	   E	   L	   Q	   S	   D	   K	   P	   T	   I	   D	   G	   W	   L	   T	   Q	   I	   D	   I	   N	   L	   N	   I	  
2	   H15N9	   A/shearwater/W.	  Australia/2576/79	   N.B	   N	   T	   E	   T	   N	   S	   P	   L	   P	   L	   I	   D	   G	   W	   Y	   T	   Q	   I	   D	   I	   T	   L	   N	   I	  
B)	  9	  






A/Puerto	  Rico/8/34(H1N1)	   4.53	  x	  105	   ≤	  5	  x	  10-­‐5	   ≤	  0.11	  x	  10-­‐9	  
A/Moscow/10/99(H3N2)	   no	  binding	   	   	  
A/duck/Czechoslovakia/56(H4N6)	   no	  binding	   	   	  
A/Vietnam/1203/2004(H5N1)	   4.30	  x	  105	   ≤	  5	  x	  10-­‐5	   ≤	  0.12	  x	  10-­‐9	  
A/duck/Alberta/60/76(H12N5)	   no	  binding	   	   	  
	  10	  
Suppl.	  Table	  2:	  A)	  Binding	  of	  Fab	  3.1	  to	  HA	  to	  different	  subtypes.	  Dissociation	  constants	  11	  
(KD)	  and	  sequences	  corresponding	  to	  mAb	  3.1	  contact	  residues	  are	  shown	  from	  different	  12	  
strains	  and	  subtypes.	  N.B.,	  no	  binding,	  N.D.,	  not	  determined,	  wt,	  wild	  type.	  Data	  were	  13	  
measured	  using	  bio-­‐layer	  interferometry	  (BLI).	  B)	  Binding	  kinetics	  (kon,	  koff	  and	  KD)	  of	  14	  
mAb3.1	  as	  determined	  by	  surface	  plasmon	  resonance	  (SPR).	  15	  





action	   Chain	   Residue	   Res.	  #	   Atom	   Chain	   Residue	   Res.	  #	   Atom	  
#	  
Interaction
s.	   Dist.(Å)	  
VDW	   HA1	   HIS	   38	   CB	   heavy	   TYR	   99	   OH	   1	   3.6	  
VDW	   HA1	   HIS	   38	   CB	   heavy	   TYR	   99	   CZ	   1	   3.6	  
VDW	   HA1	   HIS	   38	   CB	   heavy	   TYR	   99	   CE1	   1	   3.9	  
VDW	   HA1	   HIS	   38	   CB	   heavy	   TYR	   99	   CE2	   1	   4.0	  
VDW	   HA1	   HIS	   38	   CG	   heavy	   TYR	   99	   CZ	   1	   3.9	  
VDW	   HA1	   HIS	   38	   CG	   heavy	   TYR	   99	   CE1	   1	   4.0	  
VDW	   HA1	   HIS	   38	   ND1	   heavy	   TYR	   52A	   OH	   1	   3.5	  
VDW	   HA1	   HIS	   38	   ND1	   heavy	   TYR	   99	   CD2	   1	   3.7	  
VDW	   HA1	   HIS	   38	   ND1	   heavy	   TYR	   99	   CE2	   1	   3.8	  
VDW	   HA1	   HIS	   38	   CE1	   heavy	   TYR	   52A	   OH	   1	   3.7	  
VDW	   HA1	   HIS	   38	   CE1	   heavy	   TYR	   99	   CG	   1	   4.1	  
VDW	   HA1	   VAL	   40	   CB	   heavy	   PHE	   27	   CE2	   1	   3.6	  
VDW	   HA1	   VAL	   40	   CB	   heavy	   PHE	   27	   CZ	   1	   4.0	  
VDW	   HA1	   VAL	   40	   CG1	   heavy	   PHE	   27	   CE2	   1	   3.9	  
VDW	   HA1	   VAL	   40	   CG1	   heavy	   MET	   31	   CG	   1	   4.0	  
VDW	   HA1	   VAL	   40	   CG1	   heavy	   MET	   31	   SD	   1	   4.1	  
VDW	   HA1	   VAL	   40	   CG2	   heavy	   PHE	   27	   CE2	   1	   3.9	  
VDW	   HA1	   ASN	   41	   O	   heavy	   PHE	   27	   CZ	   1	   3.3	  
VDW	   HA1	   ASN	   41	   O	   heavy	   PHE	   27	   CE1	   1	   3.7	  
VDW	   HA1	   LEU	   42	   CD2	   heavy	   PHE	   27	   CZ	   1	   3.8	  
VDW	   HA1	   LEU	   42	   CD2	   heavy	   PHE	   27	   CE2	   1	   3.9	  
SHORTVDW	   HA1	   ASN	   289	   OD1	   heavy	   MET	   75	   SD	   1	   3.0	  
VDW	   HA1	   ASN	   289	   OD1	   heavy	   MET	   75	   CG	   1	   3.8	  
VDW	   HA1	   SER	   290	   N	   heavy	   MET	   75	   CE	   1	   4.0	  
VDW	   HA1	   SER	   290	   CA	   heavy	   MET	   75	   CE	   1	   4.0	  
VDW	   HA1	   SER	   290	   C	   heavy	   MET	   75	   CE	   1	   3.7	  
VDW	   HA1	   SER	   290	   O	   heavy	   MET	   75	   CE	   1	   3.9	  
H-­‐BOND	   HA1	   SER	   291	   N	   heavy	   SER	   74	   O	   1	   3.0	  
VDW	   HA1	   SER	   291	   CA	   heavy	   SER	   74	   O	   1	   3.6	  
SHORTVDW	   HA1	   SER	   291	   CB	   heavy	   SER	   74	   O	   1	   3.1	  
VDW	   HA1	   SER	   291	   CB	   heavy	   ARG	   30	   NH2	   1	   3.7	  
VDW	   HA1	   SER	   291	   CB	   heavy	   ASN	   76	   CB	   1	   3.9	  
H-­‐BOND	   HA1	   SER	   291	   OG	   heavy	   SER	   74	   O	   1	   2.9	  
H-­‐BOND	   HA1	   SER	   291	   OG	   heavy	   MET	   75	   O	   1	   3.1	  
VDW	   HA1	   SER	   291	   OG	   heavy	   MET	   75	   C	   1	   3.1	  
VDW	   HA1	   SER	   291	   OG	   heavy	   ASN	   76	   CB	   1	   3.4	  
VDW	   HA1	   SER	   291	   OG	   heavy	   MET	   75	   CE	   1	   3.4	  
VDW	   HA1	   SER	   291	   OG	   heavy	   MET	   75	   CA	   1	   3.5	  
VDW	   HA1	   SER	   291	   OG	   heavy	   ASN	   76	   N	   1	   3.6	  
VDW	   HA1	   SER	   291	   OG	   heavy	   SER	   74	   C	   1	   3.9	  
VDW	   HA1	   LEU	   292	   CD2	   heavy	   ARG	   30	   NH2	   1	   3.5	  
VDW	   HA1	   LEU	   292	   CD2	   heavy	   PHE	   27	   CE1	   1	   3.6	  
VDW	   HA1	   PRO	   293	   CD	   heavy	   PHE	   27	   CE1	   1	   3.9	  
VDW	   HA1	   PRO	   293	   CD	   heavy	   PHE	   27	   CD1	   1	   4.0	  
VDW	   HA1	   THR	   318	   CB	   heavy	   TYR	   99	   OH	   1	   3.4	  
H-­‐BOND	   HA1	   THR	   318	   OG1	   heavy	   TYR	   99	   OH	   1	   2.6	  
VDW	   HA1	   THR	   318	   OG1	   heavy	   TYR	   99	   CZ	   1	   3.6	  
VDW	   HA1	   THR	   318	   OG1	   heavy	   TYR	   99	   CE1	   1	   3.9	  
VDW	   HA1	   THR	   318	   CG2	   heavy	   TYR	   99	   OH	   1	   3.9	  
VDW	   HA1	   THR	   318	   CG2	   heavy	   MET	   31	   CE	   1	   4.0	  
VDW	   HA1	   THR	   318	   CG2	   heavy	   MET	   31	   SD	   1	   4.0	  
4	  
	  
VDW	   HA2	   ILE	   18	   O	   heavy	   PHE	   100	   CD1	   1	   3.5	  
VDW	   HA2	   ILE	   18	   O	   heavy	   PHE	   100	   CE1	   1	   3.6	  
VDW	   HA2	   ASP	   19	   C	   heavy	   PHE	   100	   CD1	   1	   3.7	  
VDW	   HA2	   ASP	   19	   O	   heavy	   PHE	   100	   CB	   1	   3.6	  
VDW	   HA2	   ASP	   19	   O	   heavy	   PHE	   100	   CG	   1	   3.7	  
VDW	   HA2	   ASP	   19	   O	   heavy	   PHE	   100	   CD1	   1	   3.8	  
VDW	   HA2	   GLY	   20	   N	   heavy	   PHE	   100	   CD1	   1	   3.5	  
VDW	   HA2	   GLY	   20	   N	   heavy	   PHE	   100	   CE1	   1	   3.7	  
VDW	   HA2	   GLY	   20	   CA	   heavy	   PHE	   100	   CE1	   1	   3.7	  
VDW	   HA2	   GLY	   20	   CA	   heavy	   PHE	   100	   CD1	   1	   3.7	  
VDW	   HA2	   GLY	   20	   CA	   heavy	   PHE	   100	   CZ	   1	   3.8	  
VDW	   HA2	   GLY	   20	   CA	   heavy	   PHE	   100	   CG	   1	   3.8	  
VDW	   HA2	   GLY	   20	   CA	   heavy	   PHE	   100	   CE2	   1	   4.0	  
VDW	   HA2	   GLY	   20	   CA	   heavy	   PHE	   100	   CD2	   1	   4.0	  
VDW	   HA2	   GLY	   20	   C	   heavy	   PHE	   100	   CZ	   1	   3.6	  
VDW	   HA2	   GLY	   20	   C	   heavy	   PHE	   100	   CE1	   1	   3.8	  
VDW	   HA2	   GLY	   20	   C	   heavy	   PHE	   100	   CE2	   1	   4.0	  
VDW	   HA2	   GLY	   20	   O	   heavy	   PHE	   100	   CZ	   1	   3.8	  
VDW	   HA2	   GLY	   20	   O	   heavy	   PHE	   100	   CE1	   1	   3.8	  
VDW	   HA2	   TRP	   21	   N	   heavy	   PHE	   100	   CZ	   1	   3.9	  
VDW	   HA2	   TRP	   21	   CG	   heavy	   PHE	   100	   CE2	   1	   3.8	  
VDW	   HA2	   TRP	   21	   CG	   heavy	   PHE	   100	   CZ	   1	   4.0	  
VDW	   HA2	   TRP	   21	   CD1	   heavy	   PHE	   100	   CZ	   1	   3.5	  
VDW	   HA2	   TRP	   21	   CD1	   heavy	   PHE	   100	   CE2	   1	   3.8	  
VDW	   HA2	   TRP	   21	   NE1	   heavy	   PHE	   100	   CZ	   1	   3.7	  
VDW	   HA2	   TRP	   21	   NE1	   heavy	   PHE	   100	   CE2	   1	   3.9	  
VDW	   HA2	   TRP	   21	   CE2	   heavy	   PHE	   100	   CE2	   1	   4.0	  
VDW	   HA2	   TRP	   21	   CD2	   heavy	   PHE	   100	   CE2	   1	   4.0	  
VDW	   HA2	   TRP	   21	   CH2	   heavy	   TYR	   99	   CE1	   1	   4.1	  
VDW	   HA2	   TRP	   21	   CH2	   heavy	   TYR	   99	   CD1	   1	   4.2	  
VDW	   HA2	   TRP	   21	   CZ2	   heavy	   TYR	   99	   CD1	   1	   3.7	  
VDW	   HA2	   TRP	   21	   CZ2	   heavy	   TYR	   99	   CE1	   1	   3.7	  
VDW	   HA2	   GLN	   38	   CB	   heavy	   ARG	   100B	   NH2	   1	   3.6	  
VDW	   HA2	   GLN	   38	   OE1	   heavy	   ARG	   100B	   NH1	   1	   3.6	  
VDW	   HA2	   GLN	   38	   OE1	   light	   TRP	   32	   CH2	   1	   3.6	  
VDW	   HA2	   GLN	   38	   OE1	   light	   TRP	   32	   CZ3	   1	   3.6	  
VDW	   HA2	   GLN	   38	   NE2	   heavy	   ARG	   100B	   CG	   1	   3.9	  
VDW	   HA2	   THR	   41	   CG2	   heavy	   PHE	   100	   CD2	   1	   3.7	  
VDW	   HA2	   THR	   41	   CG2	   heavy	   PHE	   100	   CE2	   1	   3.8	  
VDW	   HA2	   GLN	   42	   CD	   heavy	   LEU	   96	   O	   1	   3.6	  
H-­‐BOND	   HA2	   GLN	   42	   OE1	   heavy	   ARG	   100B	   NE	   1	   3.0	  
VDW	   HA2	   GLN	   42	   OE1	   heavy	   ARG	   100B	   CD	   1	   3.3	  
VDW	   HA2	   GLN	   42	   OE1	   heavy	   LEU	   96	   O	   1	   3.5	  
VDW	   HA2	   GLN	   42	   OE1	   heavy	   GLY	   97	   CA	   1	   3.6	  
H-­‐BOND	   HA2	   GLN	   42	   NE2	   heavy	   LEU	   96	   O	   1	   3.1	  
VDW	   HA2	   ILE	   45	   CG1	   heavy	   GLY	   97	   O	   1	   3.8	  
VDW	   HA2	   ILE	   45	   CD1	   heavy	   PHE	   100	   CD2	   1	   3.7	  
VDW	   HA2	   ILE	   45	   CD1	   heavy	   PHE	   100	   CE2	   1	   3.8	  
VDW	   HA2	   ILE	   45	   CG2	   heavy	   GLY	   97	   O	   1	   3.9	  
VDW	   HA2	   ILE	   45	   CG2	   heavy	   TYR	   32	   OH	   1	   4.0	  
VDW	   HA2	   THR	   49	   CA	   heavy	   THR	   28	   CG2	   1	   4.0	  
VDW	   HA2	   THR	   49	   CB	   heavy	   TYR	   32	   OH	   1	   3.5	  
VDW	   HA2	   THR	   49	   CB	   heavy	   THR	   28	   CG2	   1	   4.2	  
H-­‐BOND	   HA2	   THR	   49	   OG1	   heavy	   TYR	   32	   OH	   1	   3.2	  
SHORTVDW	   HA2	   THR	   49	   CG2	   heavy	   TYR	   32	   OH	   1	   3.2	  
SHORTVDW	   HA2	   THR	   49	   CG2	   heavy	   MET	   31	   CE	   1	   3.4	  
VDW	   HA2	   THR	   49	   CG2	   heavy	   TYR	   32	   CE2	   1	   3.5	  
5	  
	  
VDW	   HA2	   THR	   49	   CG2	   heavy	   TYR	   32	   CZ	   1	   3.8	  
VDW	   HA2	   THR	   49	   CG2	   heavy	   MET	   31	   SD	   1	   3.8	  
VDW	   HA2	   THR	   49	   CG2	   heavy	   THR	   28	   CB	   1	   3.9	  
VDW	   HA2	   THR	   49	   CG2	   heavy	   THR	   28	   CG2	   1	   4.0	  
VDW	   HA2	   THR	   49	   C	   heavy	   THR	   28	   CG2	   1	   4.1	  
VDW	   HA2	   THR	   49	   O	   heavy	   THR	   28	   CG2	   1	   3.4	  
VDW	   HA2	   VAL	   52	   CB	   heavy	   THR	   28	   CG2	   1	   3.8	  
VDW	   HA2	   VAL	   52	   CG1	   heavy	   THR	   28	   CG2	   1	   3.6	  
VDW	   HA2	   VAL	   52	   CG1	   heavy	   PHE	   27	   CD2	   1	   4.0	  
VDW	   HA2	   ASN	   53	   CG	   heavy	   THR	   28	   OG1	   1	   3.3	  
VDW	   HA2	   ASN	   53	   CG	   heavy	   THR	   28	   CG2	   1	   3.4	  
VDW	   HA2	   ASN	   53	   CG	   heavy	   THR	   28	   CB	   1	   4.0	  
H-­‐BOND	   HA2	   ASN	   53	   OD1	   heavy	   THR	   28	   OG1	   1	   3.1	  
SHORTVDW	   HA2	   ASN	   53	   OD1	   heavy	   THR	   28	   CG2	   1	   3.1	  
VDW	   HA2	   ASN	   53	   OD1	   heavy	   THR	   28	   CB	   1	   3.6	  
H-­‐BOND	   HA2	   ASN	   53	   ND2	   heavy	   THR	   28	   OG1	   1	   2.7	  
H-­‐BOND	   HA2	   ASN	   53	   ND2	   heavy	   GLU	   26	   OE1	   1	   3.3	  
VDW	   HA2	   ASN	   53	   ND2	   heavy	   THR	   28	   CG2	   1	   3.5	  
VDW	   HA2	   ASN	   53	   ND2	   heavy	   THR	   28	   CB	   1	   3.7	  
VDW	   HA2	   ILE	   56	   CD1	   heavy	   PHE	   27	   CD2	   1	   3.6	  
VDW	   HA2	   ILE	   56	   CD1	   heavy	   PHE	   27	   CG	   1	   3.6	  
VDW	   HA2	   ILE	   56	   CD1	   heavy	   PHE	   27	   CB	   1	   3.8	  
VDW	   HA2	   ILE	   56	   CD1	   heavy	   PHE	   27	   CE2	   1	   4.2	  
VDW	   HA2	   ILE	   56	   CD1	   heavy	   PHE	   27	   CD1	   1	   4.3	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Suppl.	  Table	  3:	  Interactions	  of	  mAb	  3.1	  with	  HA	  from	  A/South	  Carolina/1/1918(H1N1)	  19	  
	   	  20	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Data	  collection	   Fab	  3.1	   Fab	  3.1-­‐	  
Sc1918/H1	  HA	  	  
Beamline	   APS	  GM/CA	  CAT	  23ID-­‐B	   CLS	  
Wavelength	  (Å)	   0.71941	   0.97549	  
Space	  group	   P43	   R3	  
Unit	  cell	  parameters	  (Å,	  °)	   a	  =73.8,	  b	  =73.8,	  	  
c	  =	  207.9	  	  
α=β=γ=90	  
a	  =135.0,	  b	  =135.0,	  	  
c	  =	  230.2	  
α=β=90,	  γ=120	  
Resolution	  (Å)	  a	   50	  -­‐2.7	  (2.75-­‐	  2.70)	   50-­‐2.9	  (2.95-­‐2.90)	  
Observations	   118,373	   196,824	  
Unique	  reflections	   30,297	  (1515)	  a	   34,347	  (1706)	  
Redundancy	   3.9	  (3.8)	  a	   5.7	  (4.7)	  
Completeness	  (%)	   98.2	  (98.7)	  a	   99.6	  (96.3)	  
<I/σI>	   12.2	  (1.5)
	  a	   31.4	  (2.1)	  
Rsym
b	   0.12	  (0.65)	  a,	  b	   0.10	  (0.72)	  
Rpim
b	   0.07	  (0.43)	   0.045	  (0.38)	  
Za
c	   2	   1	  
Refinement	  statistics	   	   	  
Resolution	  (Å)	   50-­‐2.7	   50-­‐2.9	  
Reflections	  (work)	   28,423	   32,610	  
Reflections	  (test)	   2,117	   2,360	  
Rcryst(%)
d	   22.8	   19.3	  
Rfree(%)
e	   27.3	   24.1	  
Average	  B-­‐values	  (Å2)	   	   	  
	  	  	  HA	   	   84	  
	  	  	  Fab	   39	   102	  
Wilson	  B-­‐value	  (Å2)	   44	   81	  
Protein	  atoms	   6498	   7222	  
Carbohydrate	  atoms	   0	   56	  
Waters	   0	   0	  
RMSD	  from	  ideal	  geometry	   	   	  
Bond	  length	  (Å)	   0.011	   0.012	  
Bond	  angles	  (°)	   1.49	   1.48	  
Ramachandran	  statistics	  (%)g	  
	   	  
Favored	   93.1	   90.4	  
Outliers	   2.3	   1.6	  
PDB	  ID	   4PY7	   4PY8	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Suppl.	  Table	  4.	  Data	  collection	  and	  refinement	  statistics	  22	  
a	  Numbers	  in	  parentheses	  refer	  to	  the	  highest	  resolution	  shell.	  23	  
b	  Rsym	  =	  Σhkl	  Σi	  |	  Ihkl,i	  	  -­‐	  <Ihkl>	  |	  /	  Σhkl	  Σi	  Ihkl,I	  and	  Rpim	  =	  Σhkl	  (1/(n-­‐1))1/2	  Σi	  |	  Ihkl,i	  	  -­‐	  <Ihkl>	  |	  /	  Σhkl	  24	  
7	  
	  
Σi	  Ihkl,I,	  where	  Ihkl,i	  is	  the	  scaled	  intensity	  of	  the	  ith	  measurement	  of	  reflection	  h,	  k,	  l,	  <	  Ihkl	  >	  25	  
is	  the	  average	  intensity	  for	  that	  reflection,	  and	  n	  is	  the	  redundancy	  (62).	  	  26	  
c	  Za	  is	  the	  number	  of	  either	  Fab,	  HA	  monomer	  or	  HA	  monomer-­‐Fab	  complexes	  per	  27	  
crystallographic	  asymmetric	  unit.	  	  28	  
d	  Rcryst	  =	  Σhkl	  |	  Fo	  -­‐	  Fc	  |	  /	  Σhkl	  |	  Fo	  |	  x	  100	  29	  
e	  Rfree	  was	  calculated	  as	  for	  Rcryst,	  but	  on	  a	  test	  set	  comprising	  5%	  of	  the	  data	  excluded	  30	  
from	  refinement.	  31	  
f	  Calculated	  using	  Molprobity	  (53)	  32	  
	  33	  
	  34	  
